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Table 1. Recommendations 
 
Recommendation Assumed values and preferences Explanations and other considerations 
Question 1: Should a combination of oral H1-antihistamine and intranasal corticosteroid vs. intranasal corticosteroid alone be 
used for treatment of allergic rhinitis? 
Recommendation 1A 
In patients with seasonal allergic 
rhinitis, we suggest either a 
combination of an intranasal 
corticosteroid with an oral H1-
antihistamine or an intranasal 
corticosteroid alone (conditional 
recommendation | low certainty of 
evidence) 
ARIA guideline panel acknowledged that 
the choice of treatment would mostly 
depend on patient preferences and local 
availability and cost of treatment. Panel 
members assumed that in majority of 
situations, potential net benefit would not 
justify spending additional resources. 
This is a conditional recommendation, thus different 
choices will be appropriate for different patients – in 
settings where additional cost of OAH is not large 
and/or patient values and preferences differ from 
those assumed by guideline panel members a 
combination therapy may be a reasonable choice, 
especially in patients not well controlled with INCS 
alone, those with pronounced ocular symptoms or 
those commencing treatment because of likely faster 
onset of treatment effects.  
This recommendation concerns regular use of newer, 
less sedative OAH and INCS in seasonal AR. For 
older OAHs with more sedative effects the balance of 
desirable and undesirable effects may be different. 
Recommendation 1B  
In patients with perennial allergic 
rhinitis, we suggest an intranasal 
corticosteroid alone rather than a 
combination of an intranasal 
corticosteroid with an oral H1-
antihistamine (conditional 
recommendation | very low certainty 
of evidence) 
– Currently available evidence suggests that there is no 
additional benefit from a combination therapy 
compared to INCS alone and there may be additional 
undesirable effects. This recommendation is 
conditional because of sparse information, thus, very 
low certainty of the estimated effects. 
Question 2: Should a combination of intranasal H1-antihistamine (INAH) and intranasal corticosteroid vs. intranasal corticosteroid 
alone be used for treatment of allergic rhinitis? 
Recommendation 2A  
In patients with seasonal AR, we 
suggest either a combination of an 
intranasal corticosteroid with an 
intranasal H1-antihistamine or an 
intranasal corticosteroid alone 
(conditional recommendation | 
moderate certainty of evidence). 
The panel members acknowledged that 
the choice of treatment will mostly depend 
on patient preferences and local 
availability and cost of treatment. At the 
initiation of treatment (~ first 2 weeks) a 
combination of INCS with INAH may act 
faster than INCS alone and, thus, may be 
preferred by some patients. 
This is a conditional recommendation, thus different 
choices will be appropriate for different patients – in 
settings where additional cost of combination therapy 
is not large and/or patients value potential benefits 
more than any increased risk of adverse effects, a 
combination therapy may be a reasonable choice. 
Recommendation 2B  
In patients with perennial AR, we 
suggest either a combination of an 
intranasal corticosteroid with an 
intranasal H1-antihistamine or an 
intranasal corticosteroid alone 
(conditional recommendation | very 
low certainty of evidence). 
The panel members acknowledged that 
the choice of treatment will mostly depend 
on patient preferences and local 
availability and cost of treatment. 
This is a conditional recommendation because of the 
very low certainty of the evidence. At the initiation of 
treatment (~ first 2 weeks) a combination of INCS with 
INAH may act faster than INCS alone, thus, may be 
preferred by some patients. 
Question 3: Should a combination of an intranasal H1-antihistamine and an intranasal corticosteroid vs. intranasal H1-
antihistamine alone be used for treatment of allergic rhinitis? 
Recommendation 3A 
In patients with seasonal AR, we 
suggest a combination of an 
intranasal corticosteroid with an 
intranasal H1-antihistamine rather 
than an intranasal H1-antihistamine 
alone (conditional recommendation | 
low certainty of evidence) 
This recommendation places higher value 
on additional reduction of symptoms and 
improved quality of life with a combination 
therapy, compared to INAH alone. It 
places a lower value on avoiding additional 
cost (expenditure of resources). 
This is a conditional recommendation, thus different 
choices will be appropriate for different patients – in 
settings where additional cost of a combination 
therapy is large, an alternative choice, i.e. INAH alone, 
may be equally reasonable. One panel member 
thought that the recommendation should be 
conditional for either the intervention or the 
comparison. 
Question 4: Should a leukotriene receptor antagonist (LTRA) vs. an oral H1-antihistamine be used for treatment of allergic rhinitis? 
Recommendation 4A 
In patients with seasonal AR, we 
suggest either a leukotriene 
receptor antagonist or an oral H1-
antihistamine (conditional 
recommendation | moderate 
certainty of evidence) 
Panel members acknowledged that the 
choice of LTRA or OAH will mostly depend 
on patient preferences and local 
availability and cost of specific 
medications. In many settings OAH may 
still be more cost-effective but this will 
largely depend on availability of generic 
LTRA and the local cost of various newer-
generation OAH and LTRA. 
Some patients with AR who have concomitant asthma, 
especially exercise-induced and/or aspirin 
exacerbated respiratory disease, may benefit from 
LTRA more than from OAH. However, this 
recommendation applies to treatment of AR not to 
treatment of asthma. Patients with asthma who have 
concomitant AR should receive an appropriate 
treatment according to the guidelines for the treatment 
of asthma. 
Recommendation 4B 
In patients with perennial AR, we 
suggest an oral H1-antihistamine 
rather than a leukotriene receptor 
antagonist (conditional 
recommendation | low certainty of 
This recommendation places a higher 
value on possibly larger improvement of 
symptoms and quality of life with OAH, 
compared to LTRA. It places a lower value 
on possible increased risk of somnolence. 
This is a conditional recommendation, thus different 
choices will be appropriate for different patients based 
on their preferences for reduction of symptoms versus 
avoiding the risk of adverse effects – this may be more 
important for patients with PAR than with SAR as they 














Some patients with AR and concomitant asthma, 
especially exercise-induced and/or aspirin 
exacerbated respiratory disease, may benefit from 
LTRA more than from OAH. However, this 
recommendation applies to treatment of AR not to 
treatment of asthma. Patients with asthma who have 
concomitant AR should receive an appropriate 
treatment according to the guidelines for the treatment 
of asthma. 
Question 5: Should an intranasal H1-antihistamine vs. an intranasal corticosteroid be used for treatment of allergic rhinitis? 
Recommendation 5A 
In patients with seasonal AR, we 
suggest an intranasal corticosteroid 
rather than an intranasal H1-
antihistamine (conditional 
recommendation | moderate 
certainty of evidence). 
This recommendation places a higher 
value on likely small but greater reduction 
of symptoms and improvement of quality 
of life with INCS, compared to INAH, and a 
lower value on avoiding larger cost of 
treatment with INCS in many jurisdictions. 
This is a conditional recommendation, thus different 
choices will be appropriate for different patients – 
clinicians must help each patient to arrive at a decision 
consistent with her or his values and preferences 
considering local availability and costs. 
Recommendation 5B 
In patients with perennial AR, we 
suggest an intranasal corticosteroid 
rather than intranasal H1-
antihistamine (conditional 
recommendation | low certainty of 
evidence). 
This recommendation places a higher 
value on probably greater reduction of 
nasal symptoms with INCS, compared to 
INAH, although the overall difference is 
likely small. It places a lower value on 
avoiding larger cost of treatment with INCS 
in many jurisdictions. 
This is a conditional recommendation, thus different 
choices will be appropriate for different patients – 
clinicians must help each patient to arrive at a decision 
consistent with her or his values and preferences 
considering local availability and costs. 
Question 6: Should an intranasal H1-antihistamine vs. an oral H1-antihistamine be used for treatment of allergic rhinitis? 
Recommendation 6A 
In patients with SAR, we suggest 
either intranasal or oral H1-
antihistamine (conditional 
recommendation | low certainty of 
evidence). 
The panel members acknowledged that 
the choice of treatment will mostly depend 
on patient preferences and local 
availability and cost of treatment. 
This is a conditional recommendation, thus different 
choices will be appropriate for different patients – 
clinicians must help each patient to arrive at a decision 
consistent with her or his preferences, considering 
local availability, coverage, and costs. 
Recommendation 6B 
In patients with perennial AR, we 
suggest either intranasal or oral H1-
antihistamine (conditional 
recommendation | very low certainty 
of evidence). 
The panel members acknowledged that 
the choice of treatment will mostly depend 
on patient preferences and local 
availability and cost of treatment. 
This is a conditional recommendation, thus different 
choices will be appropriate for different patients – 
clinicians must help each patient to arrive at a decision 
consistent with her or his preferences, considering 















Table e1: Interpretation of strong and conditional (weak) recommendations 
Implications Strong recommendation Conditional (weak) recommendation 
For patients Most individuals in this situation would want the 
recommended course of action and only a small 
proportion would not. Formal decision aids are 
not likely to be needed to help individuals make 
decisions consistent with their values and 
preferences. 
The majority of individuals in this situation would 
want the suggested course of action, but many 
would not. 
For clinicians Most individuals should receive the intervention. 
Adherence to this recommendation according to 
the guideline could be used as a quality criterion 
or performance indicator. 
Recognize that different choices will be appropriate 
for individual patients and that you must help each 
patient arrive at a management decision consistent 
with his or her values and preferences. Decision 
aids may be useful helping individuals making 
decisions consistent with their values and 
preferences. 
For policy makers The recommendation can be adapted as policy 
or performance measure in most situations 
Policy making will require substantial debate and 
involvement of various stakeholders. 
Documentation of appropriate (e.g. shared) 
















Table e2. Recommendations 
Recommendation Assumed values and preferences Explanations and other considerations 
Question 1: Should a combination of oral H1-antihistamine and intranasal corticosteroid vs. intranasal corticosteroid alone 
be used for treatment of allergic rhinitis? 
Recommendation 1A 
In patients with seasonal allergic 
rhinitis, we suggest either a 
combination of an intranasal 
corticosteroid with an oral H1-
antihistamine or an intranasal 
corticosteroid alone (conditional 
recommendation | low certainty of 
evidence) 
ARIA guideline panel acknowledged that 
the choice of treatment would mostly 
depend on patient preferences and local 
availability and cost of treatment. Panel 
members assumed that in majority of 
situations, potential net benefit would not 
justify spending additional resources. 
This is a conditional recommendation, thus 
different choices will be appropriate for different 
patients – in settings where additional cost of 
OAH is not large and/or patient values and 
preferences differ from those assumed by 
guideline panel members a combination therapy 
may be a reasonable choice, especially in 
patients not well controlled with INCS alone, 
those with pronounced ocular symptoms or those 
commencing treatment because of likely faster 
onset of treatment effects.  
This recommendation concerns regular use of 
newer, less sedative OAH and INCS in seasonal 
AR. For older OAHs with more sedative effects 
the balance of desirable and undesirable effects 
may be different. 
Recommendation 1B  
In patients with perennial allergic 
rhinitis, we suggest an intranasal 
corticosteroid alone rather than a 
combination of an intranasal 
corticosteroid with an oral H1-
antihistamine (conditional 
recommendation | very low 
certainty of evidence) 
– Currently available evidence suggests that there 
is no additional benefit from a combination 
therapy compared to INCS alone and there may 
be additional undesirable effects. This 
recommendation is conditional because of sparse 
information, thus, very low certainty of the 
estimated effects. 
Question 2: Should a combination of intranasal H1-antihistamine (INAH) and intranasal corticosteroid vs. intranasal 
corticosteroid alone be used for treatment of allergic rhinitis? 
Recommendation 2A  
In patients with seasonal AR, we 
suggest either a combination of an 
intranasal corticosteroid with an 
intranasal H1-antihistamine or an 
intranasal corticosteroid alone 
(conditional recommendation | 
moderate certainty of evidence). 
The panel members acknowledged that 
the choice of treatment will mostly 
depend on patient preferences and local 
availability and cost of treatment. At the 
initiation of treatment (~ first 2 weeks) a 
combination of INCS with INAH may act 
faster than INCS alone and, thus, may 
be preferred by some patients. 
This is a conditional recommendation, thus 
different choices will be appropriate for different 
patients – in settings where additional cost of 
combination therapy is not large and/or patients 
value potential benefits more than any increased 
risk of adverse effects, a combination therapy 
may be a reasonable choice. 
Recommendation 2B  
In patients with perennial AR, we 
suggest either a combination of an 
intranasal corticosteroid with an 
intranasal H1-antihistamine or an 
intranasal corticosteroid alone 
(conditional recommendation | very 
low certainty of evidence). 
The panel members acknowledged that 
the choice of treatment will mostly 
depend on patient preferences and local 
availability and cost of treatment. 
This is a conditional recommendation because of 
the very low certainty of the evidence. At the 
initiation of treatment (~ first 2 weeks) a 
combination of INCS with INAH may act faster 
than INCS alone, thus, may be preferred by some 
patients. 
Question 3: Should a combination of an intranasal H1-antihistamine and an intranasal corticosteroid vs. intranasal H1-
antihistamine alone be used for treatment of allergic rhinitis? 
Recommendation 3A 
In patients with seasonal AR, we 
suggest a combination of an 
intranasal corticosteroid with an 
intranasal H1-antihistamine rather 
than an intranasal H1-
antihistamine alone (conditional 
recommendation | low certainty of 
evidence) 
This recommendation places higher 
value on additional reduction of 
symptoms and improved quality of life 
with a combination therapy, compared to 
INAH alone. It places a lower value on 
avoiding additional cost (expenditure of 
resources). 
This is a conditional recommendation, thus 
different choices will be appropriate for different 
patients – in settings where additional cost of a 
combination therapy is large, an alternative 
choice, i.e. INAH alone, may be equally 
reasonable. One panel member thought that the 
recommendation should be conditional for either 
the intervention or the comparison. 















In patients with seasonal AR, we 
suggest either a leukotriene 
receptor antagonist or an oral H1-
antihistamine (conditional 
recommendation | moderate 
certainty of evidence) 
Panel members acknowledged that the 
choice of LTRA or OAH will mostly 
depend on patient preferences and local 
availability and cost of specific 
medications. In many settings OAH may 
still be more cost-effective but this will 
largely depend on availability of generic 
LTRA and the local cost of various 
newer-generation OAH and LTRA. 
Some patients with AR who have concomitant 
asthma, especially exercise-induced and/or 
aspirin exacerbated respiratory disease, may 
benefit from LTRA more than from OAH. 
However, this recommendation applies to 
treatment of AR not to treatment of asthma. 
Patients with asthma who have concomitant AR 
should receive an appropriate treatment 
according to the guidelines for the treatment of 
asthma. 
Recommendation 4B 
In patients with perennial AR, we 
suggest an oral H1-antihistamine 
rather than a leukotriene receptor 
antagonist (conditional 
recommendation | low certainty of 
evidence) 
This recommendation places a higher 
value on possibly larger improvement of 
symptoms and quality of life with OAH, 
compared to LTRA. It places a lower 
value on possible increased risk of 
somnolence. 
This is a conditional recommendation, thus 
different choices will be appropriate for different 
patients based on their preferences for reduction 
of symptoms versus avoiding the risk of adverse 
effects – this may be more important for patients 
with PAR than with SAR as they might use those 
medications for longer periods of time. 
Some patients with AR and concomitant asthma, 
especially exercise-induced and/or aspirin 
exacerbated respiratory disease, may benefit 
from LTRA more than from OAH. However, this 
recommendation applies to treatment of AR not 
to treatment of asthma. Patients with asthma who 
have concomitant AR should receive an 
appropriate treatment according to the guidelines 
for the treatment of asthma. 
Question 5: Should an intranasal H1-antihistamine vs. an intranasal corticosteroid be used for treatment of allergic 
rhinitis? 
Recommendation 5A 
In patients with seasonal AR, we 
suggest an intranasal 
corticosteroid rather than an 
intranasal H1-antihistamine 
(conditional recommendation | 
moderate certainty of evidence). 
This recommendation places a higher 
value on likely small but greater 
reduction of symptoms and improvement 
of quality of life with INCS, compared to 
INAH, and a lower value on avoiding 
larger cost of treatment with INCS in 
many jurisdictions. 
This is a conditional recommendation, thus 
different choices will be appropriate for different 
patients – clinicians must help each patient to 
arrive at a decision consistent with her or his 
values and preferences considering local 
availability and costs. 
Recommendation 5B 
In patients with perennial AR, we 
suggest an intranasal 
corticosteroid rather than 
intranasal H1-antihistamine 
(conditional recommendation | low 
certainty of evidence). 
This recommendation places a higher 
value on probably greater reduction of 
nasal symptoms with INCS, compared to 
INAH, although the overall difference is 
likely small. It places a lower value on 
avoiding larger cost of treatment with 
INCS in many jurisdictions. 
This is a conditional recommendation, thus 
different choices will be appropriate for different 
patients – clinicians must help each patient to 
arrive at a decision consistent with her or his 
values and preferences considering local 
availability and costs. 
Question 6: Should an intranasal H1-antihistamine vs. an oral H1-antihistamine be used for treatment of allergic rhinitis? 
Recommendation 6A 
In patients with SAR, we suggest 
either intranasal or oral H1-
antihistamine (conditional 
recommendation | low certainty of 
evidence). 
The panel members acknowledged that 
the choice of treatment will mostly 
depend on patient preferences and local 
availability and cost of treatment. 
This is a conditional recommendation, thus 
different choices will be appropriate for different 
patients – clinicians must help each patient to 
arrive at a decision consistent with her or his 
preferences, considering local availability, 
coverage, and costs. 
Recommendation 6B 
In patients with perennial AR, we 
suggest either intranasal or oral 
H1-antihistamine (conditional 
recommendation | very low 
certainty of evidence). 
The panel members acknowledged that 
the choice of treatment will mostly 
depend on patient preferences and local 
availability and cost of treatment. 
This is a conditional recommendation, thus 
different choices will be appropriate for different 
patients – clinicians must help each patient to 
arrive at a decision consistent with her or his 
preferences, considering local availability, 














Box 1: Strength of recommendation 
 
Strong recommendation 
For patients: most individuals in this situation would want the recommended course of action, 
and only a small proportion would not. 
For clinicians: most individuals should receive the intervention. Adherence to a strong 
recommendation could be used as a quality criterion or performance indicator. Formal decision 
aids are not likely to be needed to help individuals make decisions consistent with their values 
and preferences. 
For health care policy makers: the recommendation can be adopted as policy or performance 
measure in most situations. 
 
Conditional recommendation 
For patients: the majority of individuals in this situation would want the suggested course of 
action, but many would not. 
For clinicians: recognize that different choices will be appropriate for individual patients and 
that you must help each patient arrive at a management decision consistent with his or her values 
and preferences. Decision aids may be useful in helping individuals to make decisions consistent 
with their values and preferences. 
For health care policy makers: policy-making will require substantial debate and involvement 
of various stakeholders. Documentation of appropriate (e.g. shared) decision-making processes 
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Clinical Implications: The 2016 revision of the ARIA guidelines offers updated 
advice for clinicians and patients about the most commonly used treatments for 
allergic rhinitis. 
 
Capsule summary: The 2016 revision of ARIA offers updated recommendations 
about the use of oral H1-antihistamines, leukotriene receptor antagonists, 
intranasal H1-antihistamines in combination with intranasal corticosteroids, and 
new recommendations about the use of combinations of oral and intranasal 
medications. 
 
Key words: allergic rhinitis, practice guideline 
 
Abbreviations: AR – allergic rhinitis, ARIA – Allergic Rhinitis and its Impact on 
Asthma, COPD – chronic obstructive pulmonary disease, EIP on AHA – 
European Innovation Partnership on Active and Healthy Ageing, EtD – 
evidence-to-decision framework, GRADE – Grades of Recommendation, 
Assessment, Development and Evaluation, ICER – incremental cost-effectiveness 
ratio, ICP – integrated care pathway, INAH – intranasal H1-antihistamine, INCS 
– intranasal corticosteroid, LTRA – leukotriene receptor antagonist, MID – 
minimal important difference, OAH – oral H1-antihistamine, PAR – perennial 
allergic rhinitis, RCT – randomized controlled trial, SAR – seasonal allergic 
rhinitis, SoF – summary of findings table, TNSS – total nasal symptom score 
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Abstract  
Background: Allergic rhinitis affects 10 to 40% of the population. It reduces 
quality of life, school and work performance, and is a frequent reason for office 
visits in general practice. Medical costs are large but avoidable costs associated 
with lost work productivity are even larger than those incurred by asthma. New 
evidence has accumulated since the last revision of the Allergic Rhinitis and its 
Impact on Asthma – ARIA guidelines in 2010 prompting its update. 
Objective: To provide a targeted update of the ARIA guidelines. 
Methods: The ARIA guideline panel identified new clinical questions and 
selected questions requiring an update. We performed systematic reviews of 
health effects and the evidence about patient values and preferences, and 
resource requirements (up to June 2016). We followed the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) 
evidence-to-decision frameworks to develop recommendations. 
Results: The 2016 revision of the ARIA guidelines provides updated and new 
recommendations about the pharmacological treatment of allergic rhinitis. It 
specifically addresses the relative merits of using oral H1-antihistamines, 
intranasal H1-antihistamines, intranasal corticosteroids, and leukotriene receptor 
antagonists either alone or their combination. The ARIA guideline panel 
provides specific recommendations for the choice of treatment, the rationale for 
the choice, and discusses specific considerations that clinicians and patients may 
want to review in order to choose the management most appropriate for an 
individual patient. 
Conclusions: Appropriate treatment of allergic rhinitis may improve patients’ 
quality of life, school and work productivity. ARIA recommendations support 





Allergic rhinitis (AR) is among the most common disea es globally and usually persists 
throughout life 1. The prevalence of self-reported AR has been estimated to be 
approximately 2 to 25% in children2 and 1 to over 40% in adults1, 3. The prevalence of 
confirmed AR in adults in Europe ranged from 17% to 28.5%. Recent studies show that 
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(for a discussion of prevalence of AR see section 5.1.– .2. in ARIA 2008 Update1). 
Classical symptoms of AR are nasal itching, sneezing, rhinorrhea, and nasal congestion. 
Ocular symptoms are also frequent; allergic rhino-conjunctivitis is associated with itching 
and redness of the eyes and tearing. Other symptoms include itching of the palate, 
postnasal drip and cough. 
AR is also frequently associated with asthma which is found in 15% to 38% of patients 
with allergic rhinitis4, 5 and that nasal symptoms are present in 6% to 85% patients with 
asthma6-9. In addition AR is a risk factor for asthma4, 9 and uncontrolled moderate-severe 
AR impacts asthma control10, 11. 
Compared to other medical conditions, AR may appear not to be serious because it is not 
associated with a severe morbidity and mortality. However, the burden and costs are 
substantial12. AR reduces quality of life of many patients impairing sleep quality and 
cognitive function, and causing irritability and fatigue. Allergic rhinitis is associated with 
decreased school and work performance, especially during the peak pollen season1. AR is 
a frequent reason for general practice office visits. Annual direct medical costs of AR are 
substantial but indirect costs associated with lost work productivity are greater than those 
incurred by asthma13-15. Appropriate treatment of AR improves symptoms, quality of life 
and work and school performance. 
Clinical practice guidelines for AR management were developed over the past 20 years 16 
and have improved the care of patients with AR 17. Transparent reporting of guidelines to 
facilitate understanding and acceptance are however needed. The ARIA (Allergic 
Rhinitis and its Impact on Asthma) initiative was initiated during a WHO workshop in 
1999 18. It was updated in 2008 1. The ARIA 2010 Revision was the first evidence-based 
guideline in allergy to follow the Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE) approach 19 with no influence of for-profit 
organizations and an explicit declaration and management of potential competing 
interests of panel members20. It summarized the potential benefits and harms underlying 
the recommendations as well as assumptions around values and preferences that 
influenced the strength and direction of the recommendations. In 2014, the ARIA 
revision was found to rank first in the rigor of development and quality of reporting of 
guidelines about the management of AR 16 although recent guidelines published later 
were not considered21. 
 
Clinical questions 
Since the last revision of the ARIA guidelines in 201020 new treatments became available 
and new evidence accumulated about selected other treatments. Using a modified Delphi 
process, the ARIA guideline panel selected new questions that required answering with 
recommendations or the existing recommendations that required an updated review of the 
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ARIA guidelines is, therefore, limited in scope and addresses 6 questions about the 
treatment of AR: 
1. Should a combination of oral H1-antihistamine (OAH) and intranasal corticosteroid 
(INCS) vs. intranasal corticosteroid alone be used for treatment of allergic rhinitis? 
2. Should a combination of intranasal H1-antihistamine (INAH) and intranasal 
corticosteroid vs. intranasal corticosteroid alone be used for treatment of allergic 
rhinitis? 
3. Should a combination of an intranasal H1-antihistamine and an intranasal 
corticosteroid vs. intranasal H1-antihistamine alone be used for treatment of allergic 
rhinitis? 
4. Should a leukotriene receptor antagonist (LTRA) vs. an oral H1-antihistamine be 
used for treatment of allergic rhinitis? 
5. Should an intranasal H1-antihistamine vs. an intranas l corticosteroid be used for 
treatment of allergic rhinitis? 
6. Should an intranasal H1-antihistamine vs. an oral H1-antihistamine be used for 
treatment of allergic rhinitis? 
The target audience of these guidelines is primary c e clinicians, school nurses, 
pharmacists, specialists in allergy and clinical immunology, general internists managing 
patients with allergic rhinitis, and pediatricians. Ear-nose-throat specialists, other health 
care professionals, and health care policy makers may also benefit from these guidelines. 
 
Classification of allergic rhinitis 
The classification of AR was revised by ARIA in 2001. A major change was the 
introduction of the terms "intermittent" and "persistent" 18. Before then, AR was 
classified, based on the time and type of exposure and symptoms, into seasonal (most 
often caused by outdoor allergens such as pollens or molds), perennial (most frequently, 
although not necessarily, caused by indoor allergens such as house dust mites, molds, 
cockroaches, and animal dander ) and occupational 22, 23. With very few exceptions 
published studies refer to seasonal and perennial allergic rhinitis and enroll patients 
based on the offending allergen (pollen and/or house dust mites) and we retained the 
terms seasonal and perennial allergic rhinitis to enable the interpretation of 
published evidence. 
The recommendations in the ARIA 2016 update apply directly to patients with moderate-
severe AR. They may be less applicable to treatment of patients with mild AR who 
frequently do not seek medical help and manage their symptoms themselves with 
medications available other-the-counter. 
 
Recommendations for children 
Almost all studies used to answer the questions in this update of the ARIA 













Page 9 of 20 
pediatric population may be attempted. One may assume that the relative effects 
of treatment of AR are likely similar among adults and children but adverse 
effects may be more or less frequent and their perception and importance may be 
different, e.g. that of a bitter taste. Values and preferences for specific outcomes 
and treatments may also vary between adults and children. 
 
Methodology 
The full description of methods used to develop recommendations in these guidelines is 
described in the Methods section of the full version of the guideline document (Online 
Repository 1). Here, we briefly describe the methodol gy to facilitate the interpretation 
of the guidelines.  
 
Questions and outcomes of interest 
 
The scope and questions for this update of the ARIA guidelines were identified by the 
ARIA guideline panel members. The guideline panel deemed the following outcomes to 
be important to patients: nasal and ocular symptoms, quality of life, work/school 
performance, and adverse effects. As for the previous revision of the ARIA guidelines we 
did not formally assess the relative importance of ach outcome of interest (i.e. which 
outcomes are more and which are less important) but rather adopted the rating agreed 
upon by the guideline panel following the structured discussion24. In general, combined 
nasal symptoms, ocular symptoms, quality of life, work/school performance, and serious 
adverse effects were considered to be critical to the decision, and individual symptoms, a 
composite outcome of any adverse effects, adverse effects that were not serious or did not 
lead to discontinuation of treatment were considere important but not critical (see 
evidence profiles in Online Repository 2).  
 
Evidence review and development of clinical recommendations 
 
For each question the methodology group performed a full systematic review of the 
literature to identify and summarize the evidence about the effects of interventions on the 
outcomes of interest. We also systematically searched for the information about patients’ 
values and preferences, and resource use (cost). We systematically searched Medline, 
Embase and Cochrane CENTRAL electronic databases. Titles and abstracts, and 
subsequently full-text articles were screened in duplicate to assess eligibility according to 
pre-specified criteria. Panel members were contacted to confirm completeness of the 
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To obtain the estimates of effects on each outcome f interest we performed meta-
analyses using the Cochrane Collaboration Review Manager Software, version 5.3.5. 25. 
We prepared evidence summaries (Online Repository 2) for each question following the 
GRADE approach 19 using the GRADEpro Guideline Development Tool online 
application (www.gradepro.org).  
 
When continuous outcomes (e.g. symptoms scores or quality of life) are measured using 
different scales, the results may only be combined  meta-analysis using standardized 
mean difference (SMD) which is expressed in standard eviation (SD) units26. Results 
expressed as a SMD are challenging to interpret. To facilitate understanding we used 
interpretation of the effect size following Cohen’s conventional criteria 27: an SMD of 
around 0.2 is considered a small effect, around 0.5 – a moderate effect, and around 0.8 or 
higher – a large effect. We used this interpretation hroughout this document whenever 
we referred to effects of interventions as small, moderate or large.  
 
We assessed the risk of bias at the outcome level using the Cochrane Collaboration’s risk 
of bias tool28. Subsequently, we assessed the certainty of the body of evidence (i.e. 
confidence in the estimated effects, also known as “quality of the evidence”) for each of 
the outcomes of interest following the GRADE approach29 based on the following 
criteria: risk of bias, precision, consistency and magnitude of the estimates of effects, 
directness of the evidence, risk of publications bias, presence of dose–effect relationship, 
and an assessment of the effect of residual, opposing confounding. Certainty of the 
evidence was categorized into 4 levels: high, moderate, low and very low. 
For each question we summarized all information in Evidence-to-Decision (EtD) 
frameworks (Online Repository 2) that included concise description of desirable and 
undesirable health effects, certainty of the evidence about those effects, evidence and 
assumptions about patients’ values and preferences, required resources and cost-
effectiveness, potential influence on health equity, acceptability of the intervention to 
various stakeholders, and feasibility of implementation 30. Judgments about all these 
factors and suggested recommendation in EtD frameworks were drafted by JLB who was 
also a clinical expert. EtDs for all questions were reviewed by the ARIA guideline panel 
members who provided feedback by electronic communication and during a face-to-face 
meeting of Integrated Care Pathways for Airway Diseases (AIRWAYS ICPs) 31, 32 and 
Frailty EIP on AHA Reference Sites in Lisbon, Portugal on July 1st, 2015 33. All 
comments were addressed and the frameworks were modified accordingly. Modified EtD 
frameworks that included judgments about the research evidence, additional 
considerations of ARIA panel members and draft recommendations were sent to all 
ARIA panel members for review and approval or disapproval and comments using the 
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all agreements/disagreements, comments and suggestions for changes. We present the 
final EtD frameworks in Online Repository 2. 
Recommendations and their strength were decided by consensus. The ARIA guideline 
panel agreed on the final wording of recommendations and remarks with further 
qualifications for each recommendation. The final document including the 
recommendations was reviewed and approved by all members of the guideline panel. 
 
According to the GRADE approach the recommendations ca  be either “strong” or 
“conditional” depending on guideline panel’s confidence that following the 
recommendation would bring more good than harm to pa ients. The wording of 
recommendations reflects their strength and one may use the words “we recommend” for 
strong recommendations and “we suggest” for conditional recommendations. Box 1 
provides suggested interpretation of strong and coniti al recommendations. 
 
Recommendations  
We present all recommendations in Table 1. We provide the rationale for the 
recommendations and the consideration of all factors that influenced the 
recommendations: effects on all important health outcomes, certainty of the 
available evidence, values and preferences, acceptability by stakeholders, 
requirements for resources, feasibility, and any issues of health equity in the 
unabridged guideline document in the Online Repository 1. Detailed summaries 
of the evidence supporting each recommendation and the guideline panel 
judgements are in the Online Repository 2. 
 
How to use these guidelines 
The ARIA guidelines about treatment of allergic rhinitis are not intended to impose a 
standard of care for individual countries. They provide the basis for rational, informed 
decisions for patients, parents, clinicians, and other health care professional. Clinicians, 
patients, third-party payers, institutional review committees, other stakeholders, or the 
courts should not view these recommendations as dictates. Recommendations provide 
guidance for typical patients – no recommendation can take into account all of the often-
compelling unique individual circumstances. Thus, no o e charged with evaluating health 
care professionals’ actions should apply the recommendations from these guidelines by 
rote or in a blanket fashion. 
Statements regarding the underlying values and preferences as well as qualifying remarks 
accompanying each recommendation should never be omitted when quoting or 
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Evidence-based guidelines are at the cornerstone of integrated care pathways (ICPs) 31, 32, 
structured multidisciplinary care plans that promote translation of guideline 
recommendations into local protocols and their subsequent application in clinical 
practice. Usually several guidelines are available providing advice about the management 
of the same condition 16. It is important to wisely choose appropriate guidelines for local 
adaptation and creation of ICPs, because most of them have limitations owing to either 
the development of the guideline itself or the available research evidence and its 
interpretation. The most common limitations of guidelines in AR are narrow scope 
(addressing only a small selection of important questions about the management of a 
given condition), suboptimal rigor of development ad reporting, and inadequate 
representation of the views of patients and their caregivers 16. We acknowledge, that for 
the ARIA 2016 update we have not reviewed all recommendations from the ARIA 2010 
but we updated only 3 recommendations suggested by the ARIA panel members as 
requiring the update and we addressed 3 new questions. We also acknowledge that the 
ARIA guideline panel included allergists, ENT specialists, pulmonologists, general 
practitioners and pediatricians but did not include other health care professionals, 
pharmacists and patients themselves. However, for the ARIA 2016 update we 
systematically searched and reviewed the published evidence about the patient values and 
preferences regarding the outcomes and treatments for AR that to certain degree helped 
to overcome this limitation. We summarized the results in the section about the assumed 
values and preferences in the full text of the ARIA 2016 update (Online Repository 1) 
and in the relevant sections of evidence-to-decision tables (Online Repository 2). 
 
The available evidence has important limitations: 1) selective measurement and reporting 
of outcomes (e.g. few studies properly measure and report quality of life which is the 
most important outcome in AR), 2) selection of patien s for clinical trials that may not 
represent appropriately the patients seen in primary c re 34 as well as 3) not 
distinguishing between patients with different age or severity of symptoms (lack of 
proper stratification) 35, thus, limiting the applicability and generalizability of the 
research findings. Given these limitations, clinical practice guidelines – especially those 
with international audience – should emphasize rigorous systematic review of the health 
effects and explicit and detailed description of the assumed values and preferences and 
considerations of cost, feasibility, acceptability and health equity issues, as it is currently 
following the GRADE evidence-to-decision frameworks 36-38. Such detailed, explicit and 
transparent reporting of guidelines facilitates loca  adaptation of recommendations and 
their translation into ICPs. Systematic and transparent summaries of the evidence clearly 
identifying gaps in available research evidence are needed to direct research agenda and 
to avoid unnecessary expenditure of resources for further clinical research when it is not 
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Implementation of guidelines in different settings and countries depends on the 
availability of health interventions (e.g. medical tests, medications, equipment, etc.), 
availability of resources, and cultural differences, among others. Thus, local adaptation of 
recommendations may be required and ICPs need to be developed at national, regional or 
local level. However, they always should be based on systematically reviewed evidence 
of desirable and undesirable consequences. The ARIA 2016 revision will be used to 
develop the ICPs proposed by the European Innovation Partnership on Active and 
Healthy Ageing 31, 32, 40 using MASK (MACVIA-ARIA Sentinel Network). ARIA is 
developing a novel implementation strategy using mobile technology 41, 42 and a clinical 
decision support system (CDSS) 41 and deployed in 21 countries 43. The ARIA 2016 
revision will be embedded in the CDSS for real-time patient stratification using mobile 
technology. 
Most of the recommendations are based on low or very low certainty evidence mainly 
because the imprecision of the estimated effects owing to few patients being studied. For 
those questions there is a need for more well design d and executed randomized 
controlled trials that would measure and properly report all important outcomes. 
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Introduction 
Since the last revision of the ARIA guidelines in 2010 E1 new treatments became available and new 
evidence accumulated about selected other treatments. The ARIA guideline panel determined new 
questions that required answering with recommendations or the existing recommendations that 
required updated review of the evidence and potentially updating the recommendations 
themselves.  
 
Clinical practice guidelines for AR management were developed over the past 20 years E2 and have 
improved the care of patients with AR E3. Transparent reporting of guidelines to facilitate 
understanding and acceptance are however needed. The ARIA (Allergic Rhinitis and its Impact on 
Asthma) initiative was initiated during a WHO workshop in 1999 E4. It was updated in 2008 E5. The 
ARIA 2010 Revision was the first chronic respiratory disease evidence-based guideline to follow the 
Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach E6 
with no influence of for-profit organizations and an explicit declaration and management of 
potential competing interests of panel members E1. It summarized the potential benefits and harms 
underlying the recommendations as well as assumptions around values and preferences that 
influenced the strength and direction of the recommendations. In 2014, the ARIA 2010 Revision was 
found to rank first in the rigor of development and quality of reporting of guidelines about the 




Allergic rhinitis (AR) is defined clinically by nasal hypersensitivity symptoms induced by an 
immunologically mediated (most often IgE-dependent) inflammation after the exposure of the nasal 
mucous membranes to an offending allergen. Symptoms of rhinitis include rhinorrhea, nasal 
obstruction or blockage, nasal itching, sneezing, and postnasal drip that are reversible 
spontaneously or with treatment. Allergic rhino-conjunctivitis often accompanies AR.  
 
Allergic rhinitis (AR) is among the most common diseases globally and usually persists throughout 
life E5. The prevalence of AR has been estimated to be approximately 2 to 25% in children E8 and 1 to 
over 40% in adults E5, E9. The prevalence of confirmed AR in adults in Europe ranged from 17% to 
28.5%. Recent studies show that the prevalence of AR has increased, in particular in countries with 
initial low prevalence (for a discussion of prevalence of AR see section 5.1.–5.2. in ARIA 2008 Update 
E5). Classical symptoms of AR are nasal itching, sneezing, rhinorrhea, and nasal congestion. Ocular 
symptoms are also frequent; allergic rhino-conjunctivitis is associated with itching and redness of 
the eyes and tearing. Other symptoms include itching of the palate, postnasal drip and cough. AR is 
also frequently associated with asthma which is found in 15% to 38% of patients with allergic 
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addition AR is a risk factor for asthma E10, E15 and uncontrolled moderate/severe AR impacts asthma 
control E16, E17. 
 
Compared to other medical conditions, AR may appear not to be serious because it is not associated 
with a high morbidity and mortality. However, the burden and costs are still substantial E18. AR 
symptoms are associated with decreased quality of life, sleep quality, energy levels, and ability to 
focus (see sections 5.3 to 5.7 in the ARIA 2008 Update) E5. The prevalence of AR has been estimated 
to be approximately 10 to 20% in the population (see sections 5.1 and 5.2 in the ARIA 2008 Update). 
AR is one of the main reasons for general practice office visits. Annual direct medical costs of AR in 
the United States alone have been estimated at from $0.8 billion in 1987 to $4.5 billion in 1997 E19-E22. 
Indirect costs associated with AR, including days missed from work or school and decreased 
productivity at work, were estimated to range from $2.4 billion to $4.6 billion in 1995 E23. Annual 
indirect costs associated with lost work productivity may be greater than those incurred by asthma 
E24-E26. An appropriate treatment of AR improves symptoms, quality of life, and work and school 
performance. 
 
Classification of allergic rhinitis 
The classification of AR was revised by ARIA in 2001 E4. A major change was the introduction of the 
terms "intermittent" and "persistent". Currently ARIA classifies allergic rhinitis according to: 
1. Duration of symptoms: 
Intermittent – symptoms are present less than 4 days a week or for less than 4 weeks.  
Persistent – symptoms are present at least 4 days a week and for at least 4 weeks.  
2. Severity of symptoms (sleep disturbance, impairment of daily activities, leisure and/or sport, 
impairment of school or work, and troublesome symptoms): 
Mild – none of the above is present. 
Moderate-severe – at least one of the above is present. 
A modification of the ARIA severity classification has been proposed. E27 
 
The recommendations in the ARIA 2016 update apply directly to patients with moderate-severe AR. 
They may be less applicable to treatment of patients with mild AR who frequently do not seek 
medical help and manage their symptoms themselves with medications available other-the-counter. 
  
Allergic rhinitis has been traditionally subdivided into seasonal, perennial, and occupational rhinitis E28, 
E29. Seasonal allergic rhinitis (SAR) is most often caused by outdoor allergens such as pollens or molds. 
Perennial allergic rhinitis (PAR) is most frequently, although not necessarily, caused by indoor 
allergens such as house dust mites, molds, cockroaches, and animal dander.  
 
With very few exceptions published studies refer to seasonal and perennial allergic rhinitis and enroll 
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document, as in the previous editions of ARIA guidelines E1, E4, E5, we retained the terms seasonal 
and perennial allergic rhinitis to enable the interpretation of published evidence.  
 
 
Approval of medications for specific indications 
The ARIA guidelines represent international effort and are meant to help patients and health care 
professionals worldwide. Thus, we explicitly decided not to take into consideration the approval 
status of individual medications in specific countries. We encourage heath care professionals and 
local organizations to consider those issues and, when needed, perform explicit adaptation of the 
ARIA guidelines to country-specific circumstances, local costs and community values and 
preferences (see section on Adaptation at the end of this document). 
 
Scope and purpose 
 
The purpose of this document is to provide guidance about the management of adults and children 
with allergic rhinitis. The recommendations in this document do not apply to treatment of other 
types of rhinitis (i.e. non-allergic) or complications of allergic rhinitis (e.g. sinusitis). 
 
This targeted revision of the ARIA guidelines is an update of the ARIA Revision 2010 E1 and is 
limited in scope. It addresses only 6 questions related to treatment of AR that were identified by the 
ARIA guideline panel. These questions either have not been asked in ARIA 2010 or the panel 
determined that they required updating owing to new evidence being available: 
1. Should a combination of oral H1-antihistamine (OAH) and intranasal corticosteroid (INCS) vs. 
intranasal corticosteroid alone be used for treatment of allergic rhinitis? 
2. Should a combination of intranasal H1-antihistamine (INAH) and intranasal corticosteroid vs. 
intranasal corticosteroid alone be used for treatment of allergic rhinitis? 
3. Should a combination of an intranasal H1-antihistamine and an intranasal corticosteroid vs. 
intranasal H1-antihistamine alone be used for treatment of allergic rhinitis? 
4. Should a leukotriene receptor antagonist (LTRA) vs. an oral H1-antihistamine be used for 
treatment of allergic rhinitis? 
5. Should an intranasal H1-antihistamine vs. an intranasal corticosteroid be used for treatment of 
allergic rhinitis? 




The target audience of these guidelines is primary care clinicians, school nurses, pharmacists, and 
specialists in allergy and clinical immunology. General internists managing patients with allergic 
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policy makers may also benefit from these guidelines. This document may also serve as the basis for 
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Clinical questions and outcomes of interest 
The scope and questions for this targeted update of the ARIA guidelines were identified by the 
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important to patients: nasal and ocular symptoms, quality of life, work/school performance, and 
adverse effects. As for the previous revision of the ARIA guidelines we did not formally assess the 
relative importance of each outcome of interest (i.e. which outcomes are more and which are less 
important) but rather adopted the rating agreed upon by the guideline panel following the 
structured discussion E30. In general, combined nasal symptoms, ocular symptoms, quality of life, 
work/school performance, and serious adverse effects were considered to be critical to the decision, 
and individual symptoms, a composite outcome of any adverse effects, adverse effects that were not 
serious or did not lead to discontinuation of treatment were considered important but not critical 
(see evidence profiles in Online Repository 2). 
 
Evidence review and development of clinical recommendations 
For each question the methodology group performed a full systematic review of the literature to 
identify and summarize the evidence about the effects of interventions on the outcomes of interest. 
We also systematically searched for the information about patients’ values and preferences, and 
resource use (cost). We systematically searched Medline, Embase and Cochrane CENTRAL 
electronic databases. Titles and abstracts, and subsequently full-text articles were screened in 
duplicate to assess eligibility according to pre-specified criteria. Panel members were contacted to 
confirm completeness of the body of evidence and suggest additional articles that might have been 
missed in electronic searches. 
 
To obtain the estimates of effects on each outcome of interest we performed meta-analyses using the 
Cochrane Collaboration Review Manager Software, version 5.3.5. E31. We prepared evidence 
summaries (Online Repository 2) for each question following the Grading of Recommendations, 
Assessment, Development and Evaluation (GRADE) approach E6 using GRADEpro Guideline 
Development Tool online application (www.gradepro.org).  
 
When continuous outcomes (e.g. symptoms scores or quality of life) are measured using different 
scales, the results may only be combined in meta-analysis using standardized mean difference 
(SMD) which is expressed in standard deviation (SD) units. Results expressed as a SMD are 
challenging to interpret. To facilitate understanding we used interpretation of the effect size 
following Cohen’s conventional criteria E32: an SMD of around 0.2 is considered a small effect, 
around 0.5 – a moderate effect, and around 0.8 or higher – a large effect. We used this interpretation 
throughout this document whenever we referred to effects of interventions as small, moderate or 
large.  
 
We assessed the risk of bias at the outcome level using the Cochrane Collaboration’s risk of bias tool 
E33. Subsequently, we assessed the certainty of the body of evidence (i.e. confidence in the estimated 
effects, also knoEwn as “quality of the evidence”) for each of the outcomes of interest following the 
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consistency, and magnitude of the estimates of effects, directness of the evidence, risk of 
publications bias, presence of dose–effect relationship, and an assessment of the effect of residual, 
opposing confounding. Certainty of the evidence was categorized into 4 levels: high, moderate, low 
and very low. 
 
For each question we summarized all information in Evidence-to-Decision (EtD) frameworks 
(Online Repository 2) that included concise description of desirable and undesirable health effects, 
certainty of the evidence about those effects, evidence and assumptions about patients’ values and 
preferences, required resources and cost-effectiveness, potential influence on health equity, 
acceptability of the intervention to various stakeholders, and feasibility of implementation E35. 
Judgments about all these factors and suggested recommendation in EtD frameworks were drafted 
by JLB who was also a clinical expert. EtDs for all questions were reviewed by ARIA guideline panel 
members who provided feedback by electronic communication and during a face-to-face meeting of 
Integrated Care Pathways for Airway Diseases (AIRWAYS ICPs) and Frailty European Innovation 
Partnership on Active and Healthy Ageing (EIP on AHA) Reference Sites in Lisbon, Portugal on July 
1st, 2015. All comments were addressed and the frameworks were modified accordingly. Modified 
EtD frameworks that included judgments about the research evidence, additional considerations of 
ARIA panel members and draft recommendations were sent to all ARIA panel members for review 
and approval or disapproval and comments using the online SurveyMonkey software 
(www.surveymonkey.com). We recorded and addressed all agreements/disagreements, comments 
and suggestions for changes. We present the final EtD frameworks in Online Repository 2. 
Following draft proposals by the methodologists, the final recommendations and their strength were 
decided by consensus. The ARIA guideline panel agreed on the final wording of recommendations 
and remarks with further qualifications for each recommendation. The final document including 
recommendations was reviewed and approved by all members of the guideline panel. 
 
We labeled the recommendations as either “strong” or “conditional” according to the GRADE 
approach. We used the words “we recommend” for strong recommendations and “we suggest” for 




Each member of the ARIA guideline panel reviewed the final draft and approved the document, 
which was then submitted for peer review with a condition that no recommendation may be 
changed at this stage, unless an error of fact or missing evidence is identified. The document was 
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Use of indirect evidence 
Pathophysiology of SAR and PAR is similar. When data for some outcomes were available only for 
SAR, we assumed that the evidence about the treatment effects in SAR would provide an indirect 
evidence about corresponding effects in PAR. The main difference is the usually long-term use of 
medications in PAR compared to mostly short-term or as needed use in SAR. Specifically, the 
adverse effects of treatments in PAR are likely to be similar to those in SAR, but there would be 
more concern about the long-term safety. In this document we explicitly stated whenever indirect 
evidence form SAR was used to inform recommendations for PAR. 
Most patients recruited into randomized controlled trials have moderate-severe AR, thus, it is 
uncertain whether or not the available evidence directly applies to patients with mild AR.  
 
(TABLE E1) 
How to use these guidelines 
 
The ARIA guidelines about treatment of allergic rhinitis are not intended to impose a standard of 
care for individual countries. They provide the basis for rational, informed decisions for 
patients, parents, clinicians, and other health care professionals. Clinicians, patients, third-party 
payers, institutional review committees, other stakeholders, or the courts should not view these 
recommendations as dictates. Recommendations provide guidance for typical patients – no 
recommendation can take into account all of the often-compelling unique individual circumstances. 
Thus, no one charged with evaluating health care professionals’ actions should apply the 
recommendations from these guidelines by rote or in a blanket fashion. 
 
Statements regarding the underlying values and preferences as well as qualifying remarks 
accompanying each recommendation should never be omitted when quoting or translating 
recommendations from these guidelines. They are integral to the recommendations and serve to 
facilitate more accurate interpretation. 
 
General issues necessary for correct interpretation and implementation of 
recommendations 
 
Assumed values and preferences of patients with SAR and PAR 
 
Outcomes 
Our systematic search for studies of values and preferences revealed 2 studies that reported utilities  
associated with different severity of AR (i.e. measures of the desirability of various outcomes to a 
patient; the value or utility of the present health state is placed on a continuum between 0 that 
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time trade-off technique E36 found utilities 0.96 associated with mild AR, 0.94 for moderate, 0.89 for 
severe and 0.83 for severest AR E37. The same study used visual analog scale (VAS) to estimate health 
status (values between 0 – worst and 1 – best) and found it to be 0.82 for mild, 0.71 for moderate, 
0.56 for severe, and 0.43 for severest AR. Another study used standard gamble technique E38 and 
found utilities ranging 0.61 to 0.69 for severe individual symptoms, and 0.44 to 0.64 for multiple 
coexisting moderate to severe symptoms E39. 
 
Several studies assessed the relative importance of individual symptoms. One study used VAS to 
assess impairment associated with individual symptoms and found largest impairment associated 
with nasal congestion (0.70), followed by nasal itching (0.79), sneezing (0.80), and ocular itching 
(0.88) E40. A survey of 1001 patients with AR in Canada showed the following symptoms were 
considered extremely bothersome: stuffed nose (26%), itchy eyes (21%), runny nose (17%), headache 
(17%), watering eyes (16%) and sneezing (14%) E41. In a sample of 83 Japanese patients nasal 
obstruction and limitation in outdoor activities were identified as the most important factors 
influencing patient satisfaction from treatment E42. 
There is some uncertainty about how generalizable are the results from these studies because there 
are differences in preference rating with the same instrument among populations in different 
countries and cultures E43. 
 
Treatments 
A cross-sectional study of 170 patients with AR examined the preferences in view of treatment and 
fear of side effects of the most common treatment options; 30% preferred a nasal spray, 25% 
preferred oral treatment and 16% preferred combination treatment, whereas 15% preferred injection 
therapy. Additionally, 48% expressed concern regarding the side effects of INCS compared to other 
treatments, 33% feared side effects of oral antihistamines, and 20% were concerned about adverse 
effects for LTRAs E44. A study in Turkey found similar results with 36% of 100 patients with AR 
perceiving INCS as being dangerous and 47% would use them if prescribed E45. Two studies found 
that patients prefer treatment options with no smell or taste E46, E47.  
 
Recommendations for children 
Almost all studies used to answer the questions in this update of the ARIA guidelines exclusively 
included adult patients. However, careful extrapolation to pediatric population may be attempted. 
One may assume that the relative effects of treatment of AR are likely similar among adults and 
children but adverse effects may be more or less frequent and their perception and importance may 
be different, e.g. that of a bitter taste. Values and preferences for specific outcomes and treatments 
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Coexisting conditions 
A recent systematic review of the prevalence of allergic rhinitis, asthma and eczema found 31 
studies among over 1.4 million children in 102 countries. The calculated worldwide prevalence was 
12.7% for allergic rhinitis, 12.00% for asthma, and 7.88% for eczema. All 3 conditions coexisted in 
1.17% of children but the risk of having all three diseases was 9.8 times higher than could be 
expected by chance. For children with allergic rhinitis the calculated risk ratio of having the other 
two disorders was 6.20 (95% CI: 5.30-7.27) E48. 
Allergic rhinitis and asthma frequently coexist – epidemiological studies suggest that asthma is 
found in as many as 15% to 38% of patients with allergic rhinitis E10, E49-E51. Some studies estimate that 
nasal symptoms are present in at least 75% of patients with asthma, but these estimates vary widely 
from 6% to 85% depending on the study E13-E15, E50, E52. Asthma is also common in the older patients 
and strongly associated with rhinitis. The risk of asthma is especially high in persistent and severe 
ARIA classification rhinitis types E49. 
 
Recommendations for specific treatment questions 
 
We present all recommendations in Table e2. Below, we provide the complete rationale for each 
recommendation and the consideration of all factors that influenced the recommendations (effects 
on all important health outcomes, certainty of the available evidence, values and preferences, 
acceptability by stakeholders, requirements for resources, feasibility, and any issues of health 
equity). Detailed summaries of the evidence supporting each recommendation and the actual 





Question 1. Should a combination of oral H1-antihistamine and intranasal corticosteroid vs. 
intranasal corticosteroid alone be used for treatment of allergic rhinitis? 
 
Intranasal corticosteroids (INCS) and oral H1-antihistamines (OAH) are the classes of medications 
most often used by patients with AR. A combination of INCS with OAH may have an advantage 
over monotherapy as their mechanisms of action are different. Their effects may be additive and 
each has specific advantages and disadvantages. 
 
Summary of the evidence 
 
We found 8 randomized controlled trials (RCTs) that compared a combined use of INCS and OAH 
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All studies in SAR included adults (1 quasi-RCT included 78 teenagers E57). Studies used a variety of 
INCS (mometasone, fluticasone and beclomethasone) and newer H1-antihistamines (loratadine, 
cetirizine and levocetirizine). Treatment duration in all studies was 2 weeks or longer. 
One study in PAR used mometasone and levocetirizine in adults for 1 month E62. The other study 
used ciclesonide and levocetirizine in adults for 3–5 weeks E61. However, only 70% patients had PAR 
and the remaining patients had SAR. 
 





In patients with SAR the additional reduction in nasal (SMD 0.13 SD lower, 95% CI: 0.25 lower to 0) 
and ocular symptoms (SMD 0.19 lower, 95% CI: 0.33 to 0.05 lower) with OAH + INCS, compared to 
INCS alone, is small and most likely would not be noticed by most patients (assuming that an SMD 
of 0.2 is a small effect and 0.5 a moderate effect). The improvement in quality of life may be large but 
available evidence does not allow to estimate it precisely enough to exclude a possibility of no effect 
or even small harm (SMD 0.61 lower, 95% CI: 1.44 lower to 0.23 higher; lower score indicates better 
quality of life). There was no evidence of that combination therapy might affect one the nasal 
symptoms more than the others (see exploratory analysis in evidence profile for question 1A in 
Online Repository 2). 
 
In patients with PAR there was no observed benefit from adding OAH to INCS, compared to INCS 
alone, in nasal symptoms (mean difference 0.2 points on a 12-point scale favoring INCS alone) and 
in ocular symptoms (mean difference 0.1 points on a 9-point scale favoring INCS alone).  
 
Harms and burden 
 
There were no serious adverse effects reported in any of the studies in SAR and PAR. There was also 
no evidence of a difference in the risk of adverse effects leading to discontinuation of therapy 
(relative risk: 0.65, but the low total number of events did not allow to estimate it precisely and the 
confidence interval does not exclude harm with either treatment option – 95% CI: 0.13 to 3.23). 
Similarly there were too few events of sedation or epistaxis to precisely estimate the difference 
between the treatments (see evidence profile for question 1A in Online Repository 2).  
 
In patients with PAR there was no difference in quality of life scores between the groups but the 
results did not exclude a possibility of importantly reduced quality of life with combination therapy, 
compared to INCS alone (mean RQLQ score was 0.2 points lower with combination therapy; 95% CI: 
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All studies in SAR and PAR investigated new generation OAH. Older generation OAH, that are 
usually more sedating, will have more adverse effects than observed in these studies. E63 
 
Decision criteria and additional considerations 
 
ARIA panel members noted that some patients beginning treatment may prefer the combination 
therapy because of faster onset of action of OAH compared to INCS alone. This, however, may be 
less important in patients with PAR than with SAR. Adherence to treatment may be lower with an 
increase in the number of medications. 
 
We found two studies that compared the cost of INCS alone to their combination with OAH –a 
retrospective database analysis using pharmacy and medical claims data from a US health plan that 
compared medical and pharmacy cost of different treatments for rhinitis E64 and a Swedish 
population-based questionnaire study that estimated an annual cost of treatment with OAH and 
INCS E65. The cost per patient varied with the ARIA classification of the severity of symptoms and 
was higher for persons with moderate to severe persistent allergic rhinitis compared to mild 
persistent disease. Panel members thought that unit costs assumed in both analyses do not reflect 
current costs in most settings and, thus, relying on those analyses could be misleading. Panel 
members agreed that additional resources required for combination therapy might be a concern in 
settings where OAH are currently more expensive but not in settings where their relative cost is not 
high. From the patient perspective, increased cost of treatment with OAH + INCS, compared to 
INCS alone, may be particularly important in settings where OAH are available other-the-counter 
and not covered by drug plans. The cost of adding OAH might therefore be relatively high, 
particularly to those individuals with limited resources. 
 
Conclusions and research needs 
 
We found little additional benefit from a combination of OAH+INCS, compared to INCS alone in 
patients with SAR. However, there may be some patients, particularly at the beginning of treatment 
that might benefit from likely faster relief of symptoms.  
ARIA guideline panel acknowledged that the choice of treatment would mostly depend on patient 
preferences and local availability and cost of treatment. Panel members felt that in majority of 
situations, where a combination therapy is considerably more expensive than INCS alone, any 
potential net benefit would not justify spending additional resources. 
There is no currently available direct evidence from experimental studies about the effects in 
subgroups based on severity of individual symptoms. However, based on indirect evidence it is 
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controlled with INCS alone, those with pronounced ocular symptoms or those at the beginning of 
treatment because of likely faster onset of treatment effect). 
All evidence is available only for new generation OAHs; for older OAHs with more sedative effects 
the balance of desirable and undesirable effects may be different. 
 
We found no additional benefit of a combination of OAH and INCS, compared to INCS alone, in 
patients with PAR. 
 
Further research of a combination of OAH with INCS as a step-up therapy in patients with not well 
controlled with INCS alone is warranted. Additional information about the effects of INCS + OAH, 
compared to INCS alone, in subpopulation of patients with pronounced ocular symptoms or those 
in whom rhinorrhea rather than congestion is the main symptom may be beneficial. Studies of real 
life effects of the combination therapy used as needed, rather than regularly, may also be warranted. 
If done, studies should measure not only nasal symptoms but also quality of life and properly report 
adverse effects. Further research to identify subgroups of patient with PAR more likely to benefit 
from H1-antihistamine added to INCS may be warranted. 
 
What others are saying 
 
The American Academy of Otolaryngology—Head and Neck Surgery guidelines offer an option: 
“clinicians may offer combination pharmacologic therapy in patients with AR who have inadequate 
response to pharmacologic monotherapy” but state that “when patients have no response to INCS or 
incomplete control of nasal symptoms with an INCS, OAH should not be routinely used as additive 
therapy” E7.  
The American Academy of Family Physicians suggests a combination of “INCS plus OAH for 
severe, persistent symptoms” but “INCS alone for the initial treatment for AR with symptoms 
affecting quality of life”. It also states that “although most patients should be treated with just one 
medication at a time, combination therapy is an option for patients with severe or persistent 
symptoms” E66. 
The Diagnosis and Management of Rhinitis: An Updated Practice Parameter developed by the Joint 
Task Force on Practice Parameters representing the American Academy of Allergy, Asthma & 
Immunology (AAAAI), the American College of Allergy, Asthma and Immunology (ACAAI) and 
the Joint Council of Allergy, Asthma and Immunology does not make explicit recommendations for 
practice but provides statements about specific treatments. It states that a “combination of OAH and 
INCS may be considered, although supporting studies are limited and many studies unsupportive 
of additive benefit of adding OAH to INCS” E67. Note that this Practice Parameter was developed in 
2008 when much less information was available. 
University of Michigan guidelines do not mention combination therapy with OAH and INCS 
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Recommendation 1A 
In patients with seasonal allergic rhinitis, we suggest either a combination of an intranasal 
corticosteroid with an oral H1-antihistamine or an intranasal corticosteroid alone (conditional 
recommendation | low certainty of evidence) 
 
Values and preferences 
The ARIA guideline panel acknowledged that the choice of treatment would mostly depend on 
patient preferences and local availability and cost of treatment. Panel members assumed that in the 
majority of situations, potential net benefit would not justify spending additional resources.  
 
Explanations and other considerations 
This is a conditional recommendation, thus different choices will be appropriate for different 
patients – in settings where additional cost of OAH is not large and/or patient values and 
preferences differ from those assumed by guideline panel members a combination therapy may be a 
reasonable choice, especially in patients not well controlled with INCS alone, those with pronounced 
ocular symptoms or those commencing treatment because of likely faster onset of treatment effects.  
This recommendation concerns regular use of newer, less sedative OAH and INCS in seasonal AR. 




In patients with perennial allergic rhinitis, we suggest an intranasal corticosteroid alone rather than 
a combination of an intranasal corticosteroid with an oral H1-antihistamine (conditional 
recommendation | very low certainty of evidence) 
 
Explanations and other considerations 
Currently available evidence suggests that there is no additional benefit from combination therapy 
compared to INCS alone and there may be additional undesirable effects. This recommendation is 
conditional because of sparse information, thus, very low certainty of the estimated effects. 
 
 
Question 2. Should a combination of intranasal H1-antihistamine and intranasal 
corticosteroid vs. intranasal corticosteroid alone be used for treatment of allergic rhinitis? 
 
A combination of INCS with INAH may have an advantage over INCS alone as their mechanisms of 
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Summary of the evidence 
 
We found 5 RCTs that compared a combination of INAH with INCS with INCS alone in patients 
with SAR. Three studies were reported together in one journal article E69. Some results from one of 
these 3 studies were published in an additional separate article E70. Of the remaining 2 studies one 
was published in 2 separate articles E71, E72 and the last one was published in 1 article E73.  
Four out of 5 studies used a combination drug in one container and one study used INCS and INAH 
as separate sprays E73. There is some uncertainty whether the desirable and undesirable effects of 
these different formulations would be the same owing to no available evidence about possible 
interactions of the two separate solutions. All 5 studies included adult patients and used fluticasone 
and azelastine nasal sprays for 2 weeks.  
 
We found 1 RCT (results published in 2 separate articles) that investigated a combination of 
fluticasone and azelastine, compared to fluticasone alone, for 52 weeks in adults with PAR E74, E75.  
 
All 6 studies in SAR and in PAR were funded by a single manufacturer of the combination drug in 
one container. Evidence profiles for question 2A (seasonal AR) and 2B (perennial AR) are in the 
Online Repository 2. 
 
We also found 6 studies that examined the time to onset of action in patients with SAR. Two studies 
presented the results only as graphs with no reported variability in results and showed that the 
difference between a combination of INAH+INCS vs. INCS alone was achieved already by day 2-3 
of treatment E71, E73. Three studies assessed nasal symptoms 4 hours after drug administration and 
found total nasal symptom score (TNSS) being reduced by 0.5 point more (95% CI: 0.07 to 0.93; scale 
0 to 24) with combination therapy compared to INCS alone E69. In the best case scenario a difference 
of 0.93 point on a 24-point scale would be unlikely to be noticed by majority of patients (we assumed 
that a difference of around 1.1 to 1.3 points on a 24-point TNSS scale would be the minimal 
important difference [MID] based on a study in SAR E76 and on an empirical observation that a 
difference of around 0.5 point on a 7-point scale is frequently an MID in respiratory diseases 
including AR E77, asthma E78-E81 and COPD82). However, in these studies patients reached 50% 
reduction of symptoms up to 3 days earlier with combination therapy compared to INCS alone. One 
study using an allergen challenge found better improvement of symptoms with INAH+INCS 
compared to INCS alone over 2-4 hours after drug administration (mean difference 1.36 point on a 
12-point scale; 95% CI: 0.87 to 1.85) E83. 
In studies that used combination therapy in one spray, one showed benefit with combination 
therapy E71 and the other did not show the difference E69. Indirect evidence from bioavailability study 
suggests that a combination of azelastine and fluticasone acts faster than fluticasone alone E84. This 
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Benefits 
 
In patients with SAR, a combination of INAH with INCS, compared to INCS alone improved nasal 
symptoms (mean difference 0.77 point lower on a 24-point scale; 95% CI: 0.3 to 1.24 lower), ocular 
symptoms (SMD 0.2 SD lower, 95% CI: 0.07 to 0.33 lower), and most likely also quality of life (mean 
difference 0.13 points in RQLQ higher, 95% CI: 0.01 to 0.24 higher). However, all effects were small 
and confidence intervals did not exclude almost no difference. A combination of azelastine and 
fluticasone acts faster than fluticasone alone. 
 
In patients with PAR, use of combination of INAH with INCS may improve nasal symptoms (mean 
score 0.27 points lower on a 24-point scale, 95% CI: 0.56 lower to 0.02 higher) although any 
difference would be small, compared to INCS alone. Combination therapy most likely increased 
number of symptom-free days by an average of 24 days during 52 weeks of treatment (95% CI: 48 
more to 0.24 fewer). Although there is no direct evidence about ocular symptoms and quality of life 
from studies in patients with PAR, indirect evidence from studies in patients with SAR suggest that 
the effect might be trivial, if any. 
 
Harms and burden 
 
There were no serious adverse effects among 1801 in 4 studies of patients with SAR. There is no 
evidence that combined therapy led to more discontinuation of treatment but confidence interval 
does not exclude an important increase of this risk (from 2 fewer to 25 more per 1000 patients). There 
were more “any adverse effects” in the combined treatment group (risk difference: 41 more per 1000 
patients, 95% CI: 12 to 81 more). All studies used azelastine as INAH and bitter taste was reported 
by some patients in combination therapy group (risk difference 26 more per 1000 patients, 95% CI: 8 
to 72 more). 
 
There were 4 serious adverse effects in the study of patients with PAR but all were very unlikely 
related to treatment (Dengue fever, pyrexia, appendicitis, and gastroenteritis). There was no 
evidence that combination treatment would lead to more discontinuation of treatment owing to 
adverse effects. Azelastine was used as INAH and bitter taste was reported by some patients in 
combination therapy group (risk difference: 20 more per 1000 patients, 95% CI: from 2 fewer to 187 
more). 
 
Decision criteria and additional considerations 
 
Panel members noted that some patients beginning treatment may prefer the combination therapy 
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We found one retrospective cohort study of adult patients with AR in the United States that 
examined the cost of INCS monotherapy, INAH monotherapy, or their combination E85. Panel 
members thought that unit costs assumed in this study do not reflect the current costs in most 
settings and relying on those estimates could be misleading. Some panel members thought that a 
combination is not cost effective compared to INCS alone, because of little – if any – additional 
benefit from a combination therapy. This may be particularly important in settings where the 
combination therapy is more expensive that INCS alone. Some panel members thought that the 
combination therapy may not be acceptable to third party payers because of cost-effectiveness. 
 
Conclusions and research needs 
 
In SAR, the additional reduction in symptoms with combination therapy is small and unlikely to be 
noticed by majority of patients. There is currently no available direct evidence from experimental 
studies about subgroups based on severity of individual symptoms of SAR. However, based on 
indirect evidence it is possible that selected patients with SAR may benefit more from a combination 
therapy (e.g. those not well controlled with INCS alone or those in whom rhinorrhea rather than 
congestion is the main complaint). 
 
Based on limited evidence in treatment of PAR, any additional reduction in symptoms with 
combination therapy, if existing, would likely be small and unlikely to be noticed by majority of 
patients.  
 
Panel members thought that in the majority of situations, both in SAR and in PAR, where a 
combination therapy is more expensive than INCS alone, any possible net benefit would not justify 
spending additional resources. 
 
Further research of a combination of INAH with INCS as a step-up therapy in patients with SAR not 
well controlled with INCS alone is warranted. A pragmatic trial in real-life setting measuring cost-
effectiveness may also be warranted. The only INAH used in these studies was azelastine and the 
only INCS was fluticasone – studies of other INAH and INCS may provide important insight. 
Further research of a combination of INAH with INCS in patients with PAR may also be justified. 
However, indirect evidence from SAR suggests that any potential benefit from combination therapy 
is likely to be trivial. Thus, further research specifically in PAR may not be cost-effective. 
 
What others are saying 
 
The American Academy of Otolaryngology—Head and Neck Surgery guidelines offer an option: 
“clinicians may offer combination pharmacologic therapy in patients with AR who have inadequate 
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spray and have inadequate control of AR symptoms with a single agent, combined INCS + INAH is 
an effective option” E7. 
The American Academy of Family Physicians suggests a combination of “INCS plus INAH for 
severe, persistent symptoms” but “INCS alone for the initial treatment for AR with symptoms 
affecting quality of life”. It also states that “although most patients should be treated with just one 
medication at a time, combination therapy is an option for patients with severe or persistent 
symptoms” E66. 
The most recent AAAAI/ACAAI Practice Parameter from 2008 does not make explicit 
recommendations for practice but states that a “combination may be considered based on limited 
data” particularly “for mixed rhinitis, there may be significant added benefit to the combination of 
INAH with INCS” E67. Note, that this Practice Parameter was developed in 2008 when less 
information was available. 
University of Michigan guidelines make no specific recommendations but state that “more recent 
evidence suggests that combination of intranasal antihistamines and intranasal corticosteroids are 




In patients with seasonal AR, we suggest either a combination of an intranasal corticosteroid with an 
intranasal H1-antihistamine or an intranasal corticosteroid alone (conditional recommendation | 
moderate certainty of evidence). 
 
Values and preferences 
The panel members acknowledged that the choice of treatment will mostly depend on patient 
preferences and local availability and cost of treatment. At the initiation of treatment (~ first 2 weeks) 
a combination of INCS with INAH may act faster than INCS alone and, thus, may be preferred by 
some patients. 
 
Explanations and other considerations 
This is a conditional recommendation, thus different choices will be appropriate for different 
patients – in settings where additional cost of combination therapy is not large and/or patients value 
potential benefits more than any increased risk of adverse effects, a combination therapy may be a 
reasonable choice.  
 
Recommendation 2B 
In patients with perennial AR, we suggest either a combination of an intranasal corticosteroid with 
an intranasal H1-antihistamine or an intranasal corticosteroid alone (conditional recommendation | 
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Values and preferences 
The panel members acknowledged that the choice of treatment will mostly depend on patient 
preferences and local availability and cost of treatment. 
 
Explanations and other considerations 
This is a conditional recommendation because of the very low certainty of the evidence. At the 
initiation of treatment (~ first 2 weeks) a combination of INCS with INAH may act faster than INCS 
alone, thus, may be preferred by some patients. 
 
 
Question 3. Should a combination of an intranasal H1-antihistamine and an intranasal 
corticosteroid vs. intranasal H1-antihistamine alone be used for treatment of allergic rhinitis? 
 
A combination of INCS with INAH may have an advantage over INAH alone as their mechanisms 
of action are different. Their effects may be additive and each has specific advantages and 
disadvantages. 
 
Summary of the evidence 
 
The same 5 RCTs in patients with SAR that compared a combination of INAH with INCS with INCS 
alone, described in question 2, used INAH alone as a second comparison group E69, E71, E73. Four out of 
5 studies used a combination drug in one container and one study used INCS and INAH as separate 
sprays E73. There also is uncertainty whether the desirable and undesirable effects of one solution 
compared to 2 separate containers would be the same owing to no available evidence about possible 
interactions of the two separate solutions. All 5 studies included adult patients and used fluticasone 
and azelastine nasal sprays for 2 weeks. All were funded by a single manufacturer of the 
combination drug in one container. Evidence profile for question 3 is in the Online Repository 2. 
 
We did not find any study that investigated a combination of INCS with INAH, compared to INAH 




There are small to moderate benefits from combined therapy. A combination of INAH with INCS, 
compared to INAH alone, reduced nasal symptoms (mean difference: 1.4 points on a 24-point scale 
lower, 95% CI: 0.98 to 1.82 lower), ocular symptoms (SMD: 0.33 SD lower, 95% CI: 0.02 to 0.65 
lower), and improved quality of life (mean difference: 0.53 points in RQLQ lower, 95% CI: 0.06 to 
1.01 lower, scale 1 to 7 and lower values indicate improvement). However, the effects could not be 
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Harms and burden 
There were no serious adverse effects in those studies. There was no evidence of an increased risk of 
any adverse effect with the combination therapy, compared to INAH alone. All studies used 
azelastine and bitter taste was reported by some patients in both groups. 
 
Decision criteria and additional considerations 
 
We found one retrospective cohort study of adult patients with AR in the United States that 
examined the cost of INAH monotherapy and a combination of INAH and INCS E85. Panel members 
thought that unit costs assumed in this study do not reflect the current costs in most settings and 
relying on the estimates from this study could be misleading. Panel members noted that the choice 
of therapy will highly depend on the local health system owing to large variability in cost and 
coverage: public or private insurance plans, co-payment models and patient out of the pocket 
expenses. Some panel members thought that, a combination therapy may not be cost effective 
compared to INAH alone. 
 
Conclusions and research needs 
 
There is a small improvement in symptoms and quality of life with a combination of INAH with 
INCS, compared to INAH alone. Mean estimates of improvement of symptoms are close to minimal 
important difference (MID) and an estimate of mean improvement in QoL is larger than MID – it is 
therefore likely that the difference would be noticed by many patients.  
 
Further research may be warranted to better estimate the effect of a combination of INAH with INCS 
on quality of life. The only INAH used in these studies was azelastine and the only INCS was 
fluticasone – studies of other INAH and INCS may be warranted. 
 
What others are saying 
 
The American Academy of Otolaryngology—Head and Neck Surgery guidelines offer an option: 
“clinicians may offer combination pharmacologic therapy in patients with AR who have inadequate 
response to pharmacologic monotherapy” and state that “in patients who tolerate INCS or INAH 
spray and have inadequate control of AR symptoms with a single agent, combined INCS + INAH is 
an effective option” E7. 
The American Academy of Family Physicians suggests a combination of “INCS plus INAH for 
severe, persistent symptoms” but “INAH as needed for mild intermittent symptoms” and adds that 
“because INAH are more expensive, less effective, and have more adverse effects than INCS, they 
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should be treated with just one medication at a time, combination therapy is an option for patients 
with severe or persistent symptoms”. 
The AAAAI/ACAAI Practice Parameter does not make explicit recommendations for practice but 
states that a “combination may be considered based on limited data” particularly “for mixed 
rhinitis, there may be significant added benefit to the combination of INAH with INCS” E67. Note 
that this Practice Parameter was developed in 2008 when much less information was available. 
University of Michigan guidelines make no specific recommendations but state that “more recent 
evidence suggests that combination of intranasal antihistamines and intranasal corticosteroids are 




In patients with seasonal AR, we suggest a combination of an intranasal corticosteroid with an 
intranasal H1-antihistamine rather than an intranasal H1-antihistamine alone (conditional 
recommendation | low certainty of evidence) 
 
Values and preferences 
This recommendation places higher value on additional reduction of symptoms and improved 
quality of life with a combination therapy, compared to INAH alone. It places a lower value on 
avoiding additional cost (expenditure of resources). 
 
Explanations and other considerations 
This is a conditional recommendation, thus different choices will be appropriate for different 
patients – in settings where additional cost of a combination therapy is large, an alternative choice, 
i.e. INAH alone, may be equally reasonable.  
One panel member thought that the recommendation should be conditional for either the 
intervention or the comparison. 
 
 
Question 4. Should a leukotriene receptor antagonist (LTRA) vs. an oral H1-antihistamine 
(OAH) be used for treatment of allergic rhinitis? 
 
Oral H1-antihistamines and leukotriene receptor antagonists (LTRA) are used for the treatment of 
AR. LTRA may have an advantage over OAH as they may cause less somnolence attributed to OAH. 
Both medications have different mechanisms of action and each may have specific advantages. In 
the 2010 revision of the ARIA guidelines we recommended OAH rather than LTRA based on lower 
cost of OAH. With the generic LTRA available since late 2012 the ARIA guideline panel decided that 
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Summary of the evidence 
 
We found 11 RCTs described in 10 articles that compared LTRA to OAH in adult patients with SAR 
E86-E95. No study included children. In 7 studies some or all patients had concomitant asthma. 
Montelukast was used in all studies except for one that used pranlukast E92. Studies used loratadine 
in the control group except for one that used cetirizine E86, another that used levocetirizine E87, and 
one that used fexofenadine E92. Follow-up was between 2 and 6 weeks. All studies were funded by 
Merck, manufacturer of montelukast, except for one that was independently funded by an academic 
institution and possibly also 2 that failed to report the source of funding. 
 
We identified one additional RCT of LTRA vs. OAH in patients with SAR but the LTRA used was 
ibudilast which is not commonly used for treatment of AR E96. We did not include this study in 
further analyses. 
 
We also found 7 RCTs of LTRA compared to OAH in patients with PAR. Five included adults E97-E101 
and 2 included children E102, E103. Five studies used montelukast and 3 used zafirlukast. Cetirizine was 
used as the control medication in 5 studies and levocetirizine, loratadine and desloratadine were 
used in one study each. All studies followed patients for 4 to 12 weeks, except for one that followed 
patients only for 2 weeks E100. However, its results were consistent with those of other studies, thus, 
we included it in the analyses. 
 





There is high certainty evidence showing that the health effects of LTRA in patients with SAR are 
similar to those of newer generation OAH: nasal symptoms (SMD: 0.06 higher, 95% CI: 0.01 lower to 
0.13 higher), ocular symptoms (SMD: 0.06 higher, 95% CI: 0.04 lower to 0.16 higher), and quality of 
life (mean difference in RQLQ score: 0.04 higher, 95% CI: 0.04 lower to 0.13 higher).  
 
In patients with PAR, the effects could not be precisely estimated owing to small number of patients 
and the evidence is of low certainty. OAH possibly reduce nasal symptoms more than LTRA (SMD: 
0.26 higher with LTRA, 95% CI: 0.45 lower to 0.97 higher) but the confidence interval does not 
exclude a moderate benefit from LTRA or a large benefit from OAH. The effect on ocular symptoms 
seemed to differ between adults (mean difference: 0.19 point lower on a 4-point scale, 95% CI: 1.03 
lower to 0.65 higher) and children (mean difference: 0.29 point higher on a 3-point scale, 95% CI: 0.04 
lower to 0.62 higher). Similarly, quality of life seemed to improve more in adults (mean difference: 
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points higher in a 138-point PRQLQ score, 95% CI: 1.66 lower to 25.66 higher). However, studies 
were very small and the differences were not large, thus, any dissimilarities in the effects between 
children and adults may be spurious.  
 
Harms and burden 
 
There were no serious adverse effects in any of the studies of SAR and PAR. There is also no 
evidence that more patients might discontinue treatment owing to adverse effects with either 
medication. There was no difference in any adverse effects observed in patients with SAR and 
somnolence was not reported in any of the studies of SAR.  
 
In patients with PAR, fewer any adverse effects were observed (14 events fewer per 100 patients 
over 6 weeks, 95% CI: 5 to 23 fewer) and less somnolence (5 fewer per 100 patients, 95% CI: 3 to 5 
fewer) with LTRA compared to OAH. However, there is low confidence that the observed results 
reflect true effects owing to limitations in study designs (see evidence profile for question 4B in 
Online Repository 2).  
 
Decision criteria and additional considerations 
 
We found one retrospective analysis of an insurance claim database in the United States that 
analyzed costs of treatment with montelukast compared with oral, branded second-generation 
antihistamines E104. We also found descriptions of two economic models that compared various OAH  
and montelukast E105, E106. However, all analyses were based on historical prices from 2000s and panel 
members thought they were not applicable today. The ARIA panel members noted that the cost of 
LTRA will frequently be higher compared to OAH but the cost of various OAH is also highly 
variable across countries and health care systems. Cost may be a more important factor for patients 
with PAR since they might use medications for longer periods of time. In settings where generic 
LTRA are available, cost of treatment may be lower compared to branded LTRA. When choosing the 
optimal treatment option clinicians need to consider the local availability and costs of LTRA and 
various OAH. Panel members also noted that many clinicians currently start therapy of AR from 
OAH rather than LTRA, most likely based on actual or perceived cost effectiveness. 
 
Panel members also noted that in some countries LTRA are currently available only for treatment of 
asthma which may be a barrier to implementation for treatment of AR. 
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There seems to be no clear difference in health outcomes between LTRA and OAH in patients with 
SAR, thus, the panel members concluded that the choice of treatment will largely depend on patient 
preferences and local availability and cost of medications. 
 
In patients with PAR, there is low certainty about the differences in health outcomes between LTRA 
and OAH – OAH may reduce symptoms and improve quality of life more but the risk of 
somnolence is possibly higher. Any true differences are likely to be small. 
 
Studies investigating the comparative effects of LTRA and OAH in patients with AR and specific 
subgroups defined by type of concomitant asthma may be warranted. 
 
What others are saying 
 
The American Academy of Otolaryngology—Head and Neck Surgery guidelines not make a specific 
recommendation for the choice of OAH or LTRA but make a separate strong recommendation to use 
“second generation/less sedating OAH for patients with AR and primary complaints of sneezing 
and itching” and a recommendation against the use of LTRA: “clinicians should not offer oral LTRA 
as primary therapy for patients with AR” E7. The rationale provided was “to reduce the use of a 
more expensive, less effective agent as first-line treatment of AR”. 
The American Academy of Family Physicians makes no specific recommendation for the use of 
LTRA versus OAH but states that “montelukast is comparable to OAH but is less effective than 
INCS” and that “it may be particularly useful in patients with coexistent asthma” E66. 
The AAAAI/ACAAI Practice Parameter does not make explicit recommendations for practice but 
states that there is “no significant difference in efficacy between LTRA and OAH” and that LTRA 
may be considered in patients who have both AR and asthma and has minimal side effects E67. Note 
that this Practice Parameter was developed in 2008 when less information was available. 
University of Michigan guidelines make no specific recommendations but state that OAH are the 
first or second and LTRA are a second or third option to add in the treatment of allergic rhinitis” E68. 
 
Recommendation 4A 
In patients with seasonal AR, we suggest either a leukotriene receptor antagonist or an oral H1-
antihistamine (conditional recommendation | moderate certainty of evidence) 
 
Values and preferences 
Panel members acknowledged that the choice of LTRA or OAH will mostly depend on patient 
preferences for the affected outcomes and local availability and cost of specific medications. In many 
settings OAH may still be more cost-effective but this will largely depend on availability of generic 
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Explanations and other considerations 
Some patients with AR who have concomitant asthma, especially exercise-induced and/or aspirin 
exacerbated respiratory disease, may benefit from LTRA more than from OAH. However, this 
recommendation applies to treatment of AR not to treatment of asthma. Patients with asthma who have 
concomitant AR should receive an appropriate treatment according to the guidelines for the 
treatment of asthma. 
 
Recommendation 4B 
In patients with perennial AR, we suggest an oral H1-antihistamine rather than a leukotriene 
receptor antagonist (conditional recommendation | low certainty of evidence) 
 
Values and preferences 
This recommendation places a higher value on possibly greater improvement of symptoms and 
quality of life with OAH, compared to LTRA. It places a lower value on possible increased risk of 
somnolence. 
 
Explanations and other considerations 
This is a conditional recommendation, thus different choices will be appropriate for different 
patients based on their preferences for reduction of symptoms versus avoiding the risk of adverse 
effects – this may be more important for patients with PAR than with SAR as they might use those 
medications for longer periods of time. 
 
Some patients with AR and concomitant asthma, especially exercise-induced and/or aspirin 
exacerbated respiratory disease, may benefit from LTRA more than from OAH. However, this 
recommendation applies to treatment of AR not to treatment of asthma. Patients with asthma who have 
concomitant AR should receive an appropriate treatment according to the guidelines for the 
treatment of asthma. 
 
 
Question 5. Should an intranasal H1-antihistamine vs. an intranasal corticosteroid be used for 
treatment of allergic rhinitis? 
 
INAH and INCS are two most effective intranasal therapies for AR. INAH may have an advantage 
over INCS in their faster onset of symptom relief as their mechanisms of action are different. In the 
2010 revision of the ARIA guidelines we recommended INCS rather than INAH. However, no well 
done systematic review was available at that time and new studies have been performed and 
published that might change the recommendation. The ARIA guideline panel decided that this 
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Summary of the evidence 
 
We identified 15 RCTs that compared INAH to INCS in patients with SAR E69, E71-E73, E107-E116 and 4 
RCTs in patients with PAR E117-E120. All studies included adult patients and none included children. 
Studies in patients with SAR used various INCS (beclomethasone, budesonide, flunisolide, 
fluticasone, and mometasone) and various INAH (azelastine, levocabastine and olopatadine) for 2 to 
6 weeks. For those studies that have not reported numerical results and/or variability in the results 
we used numbers provided in two previous systematic reviews E121, E122. We performed sensitivity 
analyses and the combined results were similar with and without those studies. 
We found some differences among different INAH and daily doses of INAH but they were not 
consistent across outcomes and there is not enough information to allow any conclusions about 
specific INAH or INCS. 
 





There seem be no desirable effects of INAH when compared to INCS in SAR and in PAR. 
 
There was no evidence of a difference in ocular symptoms in patients with SAR (SMD: 0.08 SD 
higher, 95% CI: 0.11 lower to 0.26 higher) and with PAR (mean difference: 0.29 point higher on a 5-
point scale, 95% CI: 0.39 lower to 0.97 higher).  
 
Eight studies examined the time to onset of action in patients with SAR. Results were most often 
reported as graphs with no variability and showed inconsistent results: 2 studies E110, E112 showed that 
INAH may relieve symptoms faster over the first 2-4 days with INCS being more effective from day 
4 onwards, two additional studies showed no difference E71, E73 and 4 studies showed quicker relief of 
symptoms in the INCS group E69, E111. One study using an allergen challenge found better 
improvement of symptoms with INAH compared to INCS over the first 2-4 hours after drug 
administration E83. 
 
Harms and burden 
 
In patients with SAR, effects of INAH were smaller compared to INCS on nasal symptoms (SMD: 
0.17 SD higher, 95% CI: 0.07 to 0.28 higher) and quality of life (mean difference in RQLQ score: 0.26 
points higher, 95% CI: 0.09 to 0.43 higher). However, confidence intervals around the estimated 
effects do not exclude the possibility that this difference may not be large enough to be perceived by 
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In patients with PAR, there is some evidence, albeit of low certainty, that INAH do not relieve nasal 
symptoms as well as INCS (mean difference: 1.08 points higher on a 10-point scale, 95% CI: 0.36 to 
1.8 higher). There is no information about quality-of-life in patients with PAR. However, assuming 
that symptoms are a good surrogate for quality of life, it is very likely that it would also be 
improved more with INCS. 
 
There were no serious adverse effects in any of the studies in SAR and in PAR. There was no 
evidence of higher risk of discontinuation of treatment owing to adverse effects with either 
medication. There were more any adverse effects with INAH compared to INCS in studies of SAR 
(risk difference: 35 more per 1000 patients, 95% CI: 4 to 77 more). As expected, bitter taste was more 
frequent with INAH than with INCS. Increased risk of somnolence was higher in patients with PAR 
(risk difference: 170 more per 1000 patients, 95% CI: 1 fewer to 330 more) than in SAR (risk 
difference: 3 more per 1000 patients, 95% CI: 0 to 17 more), but the confidence intervals did not 
exclude the possibility of no difference between the groups. There was no evidence of a difference in 
the risk of epistaxis. 
 
Decision criteria and additional considerations 
 
Panel members noted that relative effects of INAH and INCS may be different when used 
continuously (as in these studies) vs. as need (not investigated in clinical trials). 
 
We found one retrospective cohort study of adult patients with AR in the United States that 
examined the cost of INAH and INCS E85. Panel members thought that unit costs assumed in this 
study do not reflect the current costs in most settings and relying on the estimates from this study 
could be misleading. Panel members noted that the choice of therapy will likely highly depend on 
the local health system owing to large variability in cost and coverage among countries, healthcare 
systems, public and private insurance plans, co-payment models, and patient out of the pocket 
expenses.  
 
Conclusions and research needs 
 
There seem be no desirable effects of INAH when compared to INCS in SAR and PAR. There is 
some evidence that INCS relieve nasal symptoms better and have fewer adverse effects. However, 
the differences in the effects are small and adverse effects mild, thus, the choice may primarily 
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Further research of an effect of INAH compared with INCS on quality of life in patients with PAR 
may be warranted. The only INAH used in these 3 studies was azelastine – studies of other INAH 
may also be beneficial. 
 
What others are saying 
 
The American Academy of Otolaryngology—Head and Neck Surgery guidelines do not make a 
specific recommendation for the choice of INAH or INCS but make a separate strong 
recommendation to use INCS “for patients with a clinical diagnosis of AR whose symptoms affect 
their quality of life” and give an option to use of INAH: “clinicians may offer INAH for patients 
with seasonal, perennial, or episodic AR” E7. 
The American Academy of Family Physicians suggests “INCS alone for the initial treatment for AR 
with symptoms affecting quality of life” and “INAH as needed for mild intermittent symptoms” and 
adds that “because INAH are more expensive, less effective, and have more adverse effects than 
INCS, they are not recommended as first-line therapy for AR” E66. 
The AAAAI/ACAAI Practice Parameter does not make explicit recommendations for practice but 
states that INAH is “effective for SAR and PAR” but “less effective than INS” E67. Note that this 
Practice Parameter was developed in 2008 when less information was available. 
University of Michigan guidelines make no specific recommendations but state that INCS are the 
first and INAH are the fourth option to add in the treatment of seasonal allergic rhinitis” E68. 
 
Recommendation 5A 
In patients with seasonal AR, we suggest an intranasal corticosteroid rather than an intranasal H1-
antihistamine (conditional recommendation | moderate certainty of evidence). 
 
Values and preferences 
This recommendation places a higher value on greater reduction of symptoms and improvement of 
quality of life with INCS, compared to INAH, but and a lower value on avoiding larger cost of 
treatment with INCS in many jurisdictions. 
 
Explanations and other considerations 
This is a conditional recommendation, thus different choices will be appropriate for different 
patients – clinicians must help each patient to arrive at a decision consistent with her or his values 
and preferences considering local availability and costs. 
 
Recommendation 5B 
In patients with perennial AR, we suggest an intranasal corticosteroid rather than intranasal H1-
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Values and preferences 
This recommendation places a higher value on probably greater reduction of nasal symptoms with 
INCS, compared to INAH, although the overall difference is likely small. It places a lower value on 
avoiding larger cost of treatment with INCS in many jurisdictions. 
 
Explanations and other considerations 
This is a conditional recommendation, thus different choices will be appropriate for different 
patients – clinicians must help each patient to arrive at a decision consistent with her or his values 
and preferences considering local availability and costs. 
 
 
Question 6. Should a intranasal H1-antihistamine (INAH) vs. an oral H1-antihistamine (OAH) 
be used for treatment of allergic rhinitis? 
 
Theoretically the major advantage of INAH is the delivery directly into the nose and possible 
avoidance or reduction in severity of systemic side effects of OAH. In 2010 revision of the ARIA 
guidelines we suggested that for majority of patients OAH would be a better choice, but the 
recommendation was mainly based on indirect evidence of the likely higher patient preference for 
an oral versus intranasal route of administration.  
 
Summary of the evidence 
 
We found 9 RCTs that investigated the effects of INAH compared to OAH in patients with SAR 123-134 
and 4 studies in patients with PAR E135-E138. All studies in SAR and 3 studies in PAR included only 
adult patients; only one study in PAR included older children and teenagers E135. All studies in SAR 
and PAR used newer OAH except for 2 studies in SAR that used chlopheniramine E131, E134. Most 
studies used azelastine as INAH but one study in SAR and 2 studies in PAR used levocabastine. 
Studies in SAR followed patients for 2 to 6 weeks whereas only one study in PAR followed patient 
for at least 4 weeks 138 that is recommended for studies in PAR E139, E140. 
 





There seem to be differences in the effects among different INAH and OAH on nasal symptoms. 
There is moderate certainty evidence that azelastine has a smaller effect on nasal symptoms 
compared to cetirizine (SMD 0.21 SD higher, 95% CI: 0.06 to 0.36 higher). There is low certainty 
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(SMD 0.48 SD lower, 95% CI: 0.08 to 0.87 lower). However, in both cases confidence intervals do not 
exclude almost no effect. For all other comparisons there is no evidence that either INAH or OAH 
better relieve nasal symptoms (SMD 0 SD, 95% CI: 0.19 lower to 0.19 higher). In one study that 
measured this outcome, azelastine improved quality of life more than cetirizine (mean difference 0.3 
point in RQLQ lower, 95% CI: 0.03 to 0.57 lower).  
 
Panel members commented that there is a belief among researchers that INAH have a larger effect 
on nasal congestion, compared to OAH. We were not able to prove this effect in the 5 studies in SAR 
that reported congestion. Two studies reported end-of-study values (SMD: 0.01; 95% CI: 0.21 lower 
to 0.23 higher) and 3 studies reported changes from baseline (SMD: 0.08; 95% CI: 0.10 lower to 0.26 
higher). This observation remained almost unchanged when we included only 2 studies that used 
larger doses of INAH (SMD: 0.13; 95% CI: 0.07 lower to 0.33 higher). 
 
In patients with PAR, there was no evidence of a difference between INAH and OAH in nasal 
symptoms (SMD 0.13 higher, 95% CI: 0.12 lower to 0.39 higher) and in ocular symptoms (SMD 0.03 
higher, 95% CI: 0.23 lower to 0.28 higher). No study in PAR measured quality of life. 
 
Panel members noted that nasal congestion is an important persistent symptom of PAR. However, 
none of the studies in PAR reported the symptoms separately. 
 
Harms and burden 
 
There were no serious adverse effects in any of the trials in SAR or PAR. There was also no evidence 
of a difference in all adverse effects taken together. 
 
Patients receiving INAH, compared to OAH, were more likely to discontinue treatment owing to 
adverse effect in studies of SAR (12 more per 1000 patients , 95% CI: from 1 fewer to 41 more) but 
not PAR (2 fewer per 1000 patients, 95% CI: from 20 fewer to 248 more). Patients receiving INAH, 
compared to OAH, were less likely to experience somnolence in studies of SAR (37 fewer per 1000 
patients, 95% CI: 16 to 51 fewer) and PAR (24 fewer per 1000 patients, 95% CI: from 39 fewer to 67 
more). We have not seen any inconsistency in comparative sedating effects in 8 studies of SAR 
irrespective of the newer or older OAH being used). Bitter taste was the most common adverse effect 
of INAH (120 more per 1000 patients, 95% CI: 60 to 190 more). 
 
Decision criteria and additional considerations 
 
We found no studies comparing cost of treatment with INAH and OAH. However, as with other 
treatment of AR, cost of treatment will very much depend on local availability and cost of branded 
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Panel members noted that the availability of OAH and/or INAH other-the-counter in many 
countries may have an impact on the choice of treatment because patients’ access to one or the other 
medication may be different based on their ability to cover out of the pocket expenses. 
 
Conclusions and research needs 
 
There is no consistent evidence showing better health outcomes with INAH or OAH in SAR and in 
PAR. However the evidence is of low or very low certainty. Choice of treatment will likely depend 
on patient’s preferences for relief of specific symptoms and aversion to adverse effects – increased 
somnolence with OAH and increased bitter or perverted taste with INAH. 
 
Additional RCTs of individual INAH vs. individual OAH that properly measure and report 
symptoms and quality of life may be warranted in SAR and in PAR. Specifically, the studies that 
measure real life effects of continuous or as-needed use of INAH and OAH that also measure patient 
preference for the route of administration may be beneficial. 
 
What others are saying 
 
The American Academy of Otolaryngology—Head and Neck Surgery guidelines do not make a 
specific recommendation for the choice of INAH or OAH but make a separate strong 
recommendation to use “second generation/less sedating OAH for patients with AR and primary 
complaints of sneezing and itching” and give an option to use of INAH: “clinicians may offer INAH 
for patients with seasonal, perennial, or episodic AR” E7. 
The American Academy of Family Physicians suggests either “OAH or INAH as needed for mild 
intermittent symptoms” and adds that “although INAH are an option if symptoms do not improve 
with nonsedating OAH, their use as first- or second-line therapy is limited by adverse effects, twice 
daily dosing, cost, and decreased effectiveness compared with INCS” E66. 
The AAAAI/ACAAI Practice Parameter does not make explicit recommendations for practice but 
states that the effectiveness of INAH for AR is equal or superior to second-generation OAH E67. Note 
that this Practice Parameter was developed in 2008 when less information was available. 
University of Michigan guidelines make no specific recommendations but state that OAH are the 
first and INAH are the fourth option to add in the treatment of allergic rhinitis” E68. 
 
Recommendation 6A 
In patients with SAR, we suggest either intranasal or oral H1-antihistamine (conditional 
recommendation | low certainty of evidence). 
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The panel members acknowledged that the choice of treatment will mostly depend on patient 
preferences and local availability and cost of treatment. 
 
Explanations and other considerations 
This is a conditional recommendation, thus different choices will be appropriate for different 
patients – clinicians must help each patient to arrive at a decision consistent with her or his 
preferences, considering local availability, coverage, and costs. 
 
Recommendation 6B 
In patients with perennial AR, we suggest either intranasal or oral H1-antihistamine (conditional 
recommendation | very low certainty of evidence). 
 
Values and preferences 
The panel members acknowledged that the choice of treatment will mostly depend on patient 
preferences and local availability and cost of treatment. 
 
Explanations and other considerations 
This is a conditional recommendation, thus different choices will be appropriate for different 
patients – clinicians must help each patient to arrive at a decision consistent with her or his 
preferences, considering local availability, coverage, and costs. 
 
 
Plans for updating these guidelines 
 
Guidelines are living products. To remain useful, they need to be updated regularly as new 
information accumulates. A revision of this document will be needed, because there was limited 
evidence for many clinical questions. This document will be updated when major new research is 
published. The need for update will be determined not later than in 2020.  
 
Updating or adapting recommendations locally  
 
The methods used to develop these guidelines are transparent. The recommendations have been 
developed to be as specific and detailed as possible without losing sight of the simplicity of the 
document. Since ARIA are meant as international guidelines, the guideline panel encourages 
feedback on all its aspects including applicability of recommendations in individual countries.E141 
This feedback will be considered with the next revision of ARIA guidelines.  
Adaptation of ARIA guidelines will be necessary in many circumstances and we suggest that 
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de novo creation of recommendations, with collaboration of the authors of this document. 
Depending on when such a process takes place, the following steps are part of that process: 
• Appointing a guideline committee comprising clinicians and methodologists 
• Determining the scope of the local guidelines 
• Defining the relevant clinical questions to be addressed in local guidelines 
• Updating the evidence profiles and Evidence-to-Decision tables, if necessary 
• Reviewing the recommendations in the ARIA guidelines (the recommendations may need to 
be modified at a local level, depending on the local values and preferences, availability of 




Evidence-based guidelines are at the cornerstone of integrated care pathways (ICPs) E142, E143, 
structured multidisciplinary care plans that promote translation of guideline recommendations into 
local protocols and their subsequent application in clinical practice. Usually several guidelines are 
available providing advice about the management of the same condition E2. It is important to wisely 
choose appropriate guidelines for local adaptation and creation of ICPs, because most of them have 
limitations owing to either the development of the guideline itself or the available research evidence 
and its interpretation. The most common limitations of guidelines in AR are narrow scope 
(addressing only a small selection of important questions about the management of a given 
condition), suboptimal rigor of development and reporting, and inadequate representation of the 
views of patients and their caregivers E2. We acknowledge, that for the ARIA 2016 update we have 
not reviewed all recommendations from the ARIA 2010 but we updated only 3 recommendations 
suggested by the ARIA panel members as requiring the update and we addressed 3 new questions. 
We also acknowledge that the ARIA guideline panel included allergists, ENT specialists, 
pulmonologists, general practitioners and pediatricians but did not include other health care 
professionals, pharmacists and patients themselves. However, for the ARIA 2016 update we 
systematically searched and reviewed the published evidence about the patient values and 
preferences regarding the outcomes and treatments for AR that to certain degree helped to 
overcome this limitation. We summarized the results in the section about the assumed values and 
preferences above and in the relevant sections of evidence-to-decision tables (Online Repository 2). 
 
The available evidence has important limitations: 1) selective measurement and reporting of 
outcomes (e.g. few studies properly measure and report quality of life which is the most important 
outcome in AR), 2) selection of patients for clinical trials that may not represent appropriately the 
patients seen in primary care E144 as well as 3) not distinguishing between patients with different age 
or severity of symptoms (lack of proper stratification) E145, thus, limiting the applicability and 
generalizability of the research findings. Given these limitations, clinical practice guidelines – 













Brozek J et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines – 2016 Revision 
Page 36 of 49 
health effects and explicit and detailed description of the assumed values and preferences and 
considerations of cost, feasibility, acceptability and health equity issues, as it is currently following 
the GRADE evidence-to-decision frameworks E146-E148. Such detailed, explicit and transparent 
reporting of guidelines facilitates local adaptation of recommendations and their translation into 
ICPs. Systematic and transparent summaries of the evidence clearly identifying gaps in available 
research evidence are needed to direct research agenda and to avoid unnecessary expenditure of 
resources for further clinical research when it is not necessary E149.  
 
Implementation of guidelines in different settings and countries depends on the availability of 
health interventions (e.g. medical tests, medications, equipment, etc.), availability of resources, and 
cultural differences, among others. Thus, local adaptation of recommendations may be required and 
ICPs need to be developed at national, regional or local level. However, they always should be 
based on systematically reviewed evidence of desirable and undesirable consequences. The ARIA 
2016 revision will be used to develop the ICPs proposed by the European Innovation Partnership on 
Active and Healthy Ageing E142, E143, E150 using MASK (MACVIA-ARIA Sentinel Network). ARIA is 
developing a novel implementation strategy using mobile technology E151, E152 and a clinical decision 
support system (CDSS) E151 and deployed in 21 countries E153. The ARIA 2016 revision will be 
embedded in the CDSS for real-time patient stratification using mobile technology. 
Most of the recommendations are based on low or very low certainty evidence mainly because the 
imprecision of the estimated effects owing to few patients being studied. For those questions there is 
a need for more well designed and executed randomized controlled trials that would measure and 
properly report all important outcomes. 
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